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1 Mitochondria 
 
Structure 
 
Mitochondria are rod-shaped organelles and can be considered the power 
generators of the cell, converting oxygen and nutrients into adenosine 
triphosphate (ATP). ATP is the chemical energy "currency" of the cell that 
powers the cell's metabolic activities. Mitochondria, which are found in nearly 
all eukaryotes, including plants, animals, fungi, and protists, are large enough 
to be observed with a light microscope and were first discovered in the 1800s. 
The name of the organelles was coined to reflect the way they looked to the 
first scientists to observe them, stemming from the Greek words for "thread" 
and "granule."  Mitochondria are usually represented like single entities in the 
images obtained by electron microscopy (figure 1)  but in living cells they 
appear more like a continuous tubular network, when they are detected by 
fluorescence microscopy (figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 1 Mitochondrion: electron microscopy of a sectional view 
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Mitochondria include two phospholipid bilayers with embedded proteins that 
define four compartments, where different metabolic processes take place: the 
mitochondrial outer membrane (MOM), the intermembrane space, the 
mitochondrial inner membrane (MIM) and the matrix (the space enclosed by 
the inner membrane) (figure 3). It has been estimated that some 1500 different 
proteins are found in the various mitochondrial compartments where they have 
specific functions [1]. 
 
 
 
figure 3. Mitochondrion: schematic  rapresentation 
figure 2. Fluorescence emission intensity from a culture of bovine pulmonary artery 
endothelial cells stained with MitoTracker Red, which targets the intracellular 
mitochondrial network. 
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Proteins localized in the MOM are integral membrane proteins with one or 
more membrane-spanning regions or membrane-associated peripheral 
proteins. These membrane proteins are involved in solute exchange between 
the cytosol and intermembrane space, protein import into mitochondria, 
docking sites for cytosolic proteins, and uptake of activated fatty acids into the 
mitochondria]. MOM proteins account for approximately 4% of the total 
mitochondrial protein [1]. 
The intermembrane space is delimited by the outer and inner membrane and 
has a protein composition different from the cytosol and matrix, in part due to 
the specific amino acid sequences needed to cross the outer as well as the 
inner membrane. The protein content of this space is much lower than that of 
the matrix (about 6% of the total mitochondrial protein). The main protein is 
cytochrome c, which is involved in respiration in normal cells and in apoptosis. 
Other potential apoptotic inducers are present, as well as enzymes such as 
adenylate kinase and creatine kinase. 
Approximately 21% of the total mitochondrial protein is localized in the MIM. In 
contrast to the MOM, it has a high protein:phospholipid ratio (more than 3:1 by 
weight) and is rich in cardiolipin. The MIM is highly impermeable to all anidrous 
molecules, therefore solutes require specific transporters to enter or exit the 
matrix [2]. 
It also contains the translocase of the inner membrane (TIM) complex, which 
catalyzes the import of proteins into the matrix with the translocase of the outer 
membrane (TOM) complex. 
The inner mitochondrial membrane is compartmentalized into numerous 
cristae, which expand the surface area of the inner mitochondrial membrane, 
enhancing its ability to produce ATP. The cristae are invaginations of the inner 
membrane, which can affect overall chemiosmotic function. The cristae 
contain the electron transport chain (ETC) complexes (complexes I–IV) and 
ATP synthetase (complex V). Mitochondria of cells that have greater demand 
for ATP, such as muscle cells, contain more cristae than liver mitochondria [3].   
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The matrix is the space enclosed by the inner membrane containing about 
two-thirds of the total protein in a mitochondrion, it contains a highly 
concentrated mixture of hundreds of enzymes, in addition to the special 
mitochondrial ribosomes, tRNA, and several copies of the mtDNA. Most of the 
enzymes in the matrix are involved in the oxidation of pyruvate and fatty acids 
and the Krebs cycle [4]. 
 
 
           Mitochondrial genome 
 
The mitochondria are ancient bacterial symbionts with their own mitochondrial 
DNA (mtDNA), RNA, and protein synthesizing systems. Each human cell 
contains hundreds of mitochondria and thousands of mtDNAs. The mtDNA is 
maternally inherited and shows striking regional genetic variation. This 
regional variation was a major factor in permitting humans to adapt to the 
different global environments they encountered and mastered [5]. 
mtDNA retains only the genes for the 12S and 16S rRNAs and the 22 tRNAs 
required for mitochondrial protein synthesis plus 13 polypeptides of the 
mitochondrial energy generating process, oxidative phosphorylation 
(OXPHOS). The remaining ∼1500 genes of the mtDNA are now scattered 
throughout the chromosomal DNA. These nDNA-encoded mitochondrial 
proteins are translated on cytosolic ribosomes and selectively imported into 
the mitochondrion through various mitochondrial protein import systems  [5]. 
mtDNA is a double‐stranded circular DNA molecule of approximately 16.5 kb 
in all mammals in which it has been sequenced (figure 4). The two strands are 
referred to as heavy (H) and light (L), reﬂecting their behavior in density 
gradients.  
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The genome is exceedingly compact; there are no introns, and there is only 
one noncoding (control) region of approximately 1 kb that contains the 
replication origin for leading strand synthesis (OH), and the promoters for 
transcription of the H‐ and L‐strands. The mtDNA copy number in somatic cells 
is generally is about a hundred copies per cell, packaged in a DNA‐protein 
structure called the nucleoid at approximately 2–10 copies per nucleoid [6]. 
Investigation of the protein constituents of the yeast mitochondrial nucleoid by 
mass spectrometry has revealed a large number of proteins, some of which 
have dual functions in nucleoid maintenance and tricarboxylic acid cycle 
activity [7].  
The mitochondrial nucleoid in higher eukaryotes is reported to contain TFAM, 
a mitochondrial transcription factor, single‐stranded binding protein, Twinkle (a 
helicase), and at least four additional inner membrane proteins.  TFAM is a 
basic protein of the HMG box family that is thought to package mtDNA. 
Decreasing TFAM levels results in loss of mtDNA [6]. 
 
 
Mitochondrial Oxidative Phosphorylation 
 
In most human tissues, mitochondria provide the energy necessary for cell 
growth, and biological activities. It has been estimated that  90% of 
figure 4. Human Mitochondrial DNA 
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mammalian oxygen consumption is mitochondrial, which primarily serves to 
synthesize ATP, although in variable levels according to the tissue considered 
and the organism’s activity status.  
Mitochondria intervene in the ultimate phase of cellular catabolism, following 
the enzymatic reactions of intermediate metabolism that degrade 
carbohydrates, fats, and proteins into smaller molecules such as pyruvate, 
fatty acids, and amino acids. 
Mitochondria further transform these energetic elements into NADH and/or 
FADH2, through β-oxidation and the Krebs cycle. Those reduced equivalents 
are then degraded by the mitochondrial respiratory chain in a global energy 
converting process called oxidative phosphorylation  (OXPHOS),  where the 
electrons liberated by the oxidation of NADH and FADH2 are passed along a 
series of carriers regrouped under the name of “respiratory chain” or “electron 
transport chain” (ETC) , and ultimately transferred to molecular oxygen. ETC is 
located in the mitochondrial inner membrane, with an enrichment in the 
cristae. ETC consists of four enzyme complexes (complexes I to IV), and two 
mobile electron carriers (coenzyme Q and cytochrome c). These complexes 
are composed of numerous subunits encoded by both nuclear genes and 
mitochondrial DNA at the exception of complex II (nuclear only) [2]. 
ETC complexes transfer electrons deriving from NADH and FADH2 to 
molecular oxygen producing water (figure 5). The oxygen reduction occurs 
through a multi-steps process: Complex I (NADH:Ubiquinone oxidoreductase) 
or Complex II (Succinate:Ubiquinone oxidoreductase) transfer two electrons 
deriving from NADH or FADH2 to CoQ giving ubisemiquinone (CoQ•) and then 
ubiquinol (CoQH2).  
 
Complex II is the only enzyme of respiratory chain that does not show proton-
pumping activity but it represents an alternative entry point for electrons and a 
checkpoint for the coordination between Krebs cycle and oxidative 
phosphorylation [8]. 
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Complex II is composed of four subunits all encoded by nuclear genes: the two 
largest subunits lie in the matrix space and contain a covalently bound flavine 
adenine dinucleotide together with three Fe-S clusters. The other two subunits, 
less conserved, are localized in the membrane and contain a type b heme and 
two ubiquinone/ubiquinol binding domains localized on opposite sites of the 
inner membrane. The large distance between the two quinones would suggest 
that only the quinone bound near the cytplasmic side of inner membrane is 
part of the electron transfer chain. The catalytic mechanism consists in the 
reduction of FAD by the succinate molecule followed by electron transfer to 
CoQ through the Fe-S clusters chain. The role of heme b is not yet clearly 
understood. Besides its potential structural role, this prosthetic group could 
take part to redox reactions only during reverse electron transfer, being 
capable to participate in fumarate reduction but not in succinate oxidation  [9-
10].  
Ubiquinol is oxidized by Complex III (Ubiquinol:Cytochrome c oxidoreductase) 
which reduces cytochrome c. Complex III exists as symmetric dimer where 
each monomer consists of eleven subunits. 
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figure 5. Schematic representation of OXPHOS system (from Helsinki Bioenergetics Group, 
Institute of Biotechnology, Finland). 
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The catalytic core is formed by three subunits containing all the redox centers of the 
enzyme: cytochrome b, cytochrome c1 and an iron-sulfur protein known as Rieske 
protein. Cytochrome b contains two heme groups – b565 and b560 – and two 
ubiquinone/ubiquinol binding sites called P center and N center; cytochrome c1 is the 
cytochrome c electron donor. The redox proteins along with other three subunits [11] 
(OMIM- Online Mendelian Inheritance in Man) span the inner membrane while the 
remaining subunits are exposed to the matrix or to the intermembrane space. The 
catalytic mechanism is characterized by oxidation of ubiquinol and reduction of 
ubiquinone during the Q-Cycle. This process allows the translocation of four protons 
across the membrane and it occurs through one-electron steps oxidation of ubiquinol. 
Briefly, one electron deriving from the ubiquinol on the P 10 center sequentially flows 
from the high-potential Fe2-S2 cluster to cytochrome c1 and cytochrome c. The 
ubiquinol oxidation is completed through a different pathway: the second electron 
reduces heme b560, heme b565 and finally a molecule of ubiquinone bound at the N 
center to its ubisemiquinone form. 
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The cycle ends with the binding of a second CoQH2 at the P center: in this 
case, the first electron is used to reduce a second cytochrome c molecule 
while the other flows through heme b565 and b560 to reduce the 
ubisemiquinone at the N center determining the uptake of two protons from the 
matrix. The complete reaction can be so represented:  
 
QH2 + 2 cyt cox  + 2H
+
matrix → Q + 2 cyt cred + 4H
+
intermembrane space 
 
From cytochrome c electrons flow to Complex IV (Cytochrome c oxidase) that 
finally reduces molecular oxygen to water. Complex IV is composed of thirteen 
subunits; three of them - I, II and III - are encoded by mitochondrial genes and 
represent the catalytic core of the enzyme. In subunit I are localized a copper 
atom - CuB - and two heme groups, called a and a3. Subunit II contains CuA, 
a binuclear copper center. The catalytic action occurs through Cytochrome c 
oxidation by CuA. Heme a represents the bridge between CuA and the heme-
copper center formed by CuB and heme a3 where molecular oxygen is bound 
and reduced to water [12]. 
Nevertheless subunit III is well conserved during evolution, its function still 
remains uncertain: the absence of redox centers excludes its participation to 
electron transfer. Moreover, studies in P. denitrificans have showed that a 
cytochrome oxidase lacking of subunit III conserves the capacity of translocate 
protons suggesting that this subunit is not determinant for proton pumping.  
The oxygen reduction by Complex IV occurs through a multi-steps mechanism 
in which different iron-oxygen intermediates are formed thanks to the 
cooperation between heme a3 and CuB. The electron transfer is coupled with 
the uptake of an equal number of protons from the matrix so that for each 
complete cycle four protons are vectorially translocated into the 
intermembrane space. The complex is provided with three potential channels 
by which proton transport can be accomplished. The so-called K channel 
allows the access of the four protons to the binuclear site for water formation, 
whereas D and H channels span the entire membrane layer. These channels 
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are characterized by amino acids with protonable side chain, capable to form 
hydrogen bonds with nearby amino acids and to create a bridge between the 
matrix and the intermembrane space. However, site-directed mutagenesis 
studies, performed with the bacterial enzyme, suggest that the H channel is 
not involved in proton translocation. The nuclear-encoded subunits exposed 
ether to the matrix or to the intermembrane space, are not directly involved in 
the catalytic mechanism and are supposed to have a regulatory function [13].  
The energy released by the exergonic electron transfer to the oxygen is then 
converted in what P. Mitchell, who first proposed the chemiosmotic theory, 
called protonmotive force. Contextually to the redox reactions Complex I, III 
and IV pump protons from the matrix into the intermembrane space so that 
through the inner membrane is established an electrochemical gradient (ΔP) 
consisting of two components: ΔΨ (electric) and ΔpH (chemical).  
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Complex V (ATP synthase) converts the energy stored in ΔP in high-energy 
phosphate bonds readily available for cell demand. Complex V F0 sector, 
embedded in the inner membrane, contains a channel that allows to protons to 
flow back to the matrix thanks to the electrochemical gradient. The energy 
released by ΔP dissipation is linked to ATP synthesis by the Complex V 
soluble portion, F1, through a tree steps mechanism in which ADP and Pi are 
bound and condensed to form ATP that is finally released into the matrix. The 
mammalian F0 component contains nine subunits (a, b, c, d, e, f, g, A6L, F6), 
while the F1 hydrophilic component has a α3, β3, γ, δ, ε composition where β 
subunits represent the active sites for the ATP synthesis. In the inner 
membrane 8-12 c subunits are arranged in a ring connected by a stalk to the 
catalytic component in the hydrophilic portion. The γ, δ and ε subunits 
compose the central part of the stalk moiety, while the peripheral stalk, lying to 
one side of the complex is composed of b, d, F6 and OSCP (oligomycin 
sensitivity conferring protein) subunits [13]. 
Complex V works as a rotary motor in which the protons flow through the F0 
portion modulates the properties of the β subunits. The catalytic subunits exist 
in three different conformations associated with different affinity for ADP-Pi 
and ATP, according to the binding-change mechanism proposed by Boyer 
[14]. 
The energy deriving from proton gradient dissipation is actually needed to 
eliminate the strong interaction between the newly synthesized ATP and the 
catalytic site. The transition between the three different β conformations is 
driven by the rotation of γ subunit. The b subunit along with other stalk 
components works as a tether between the F0 and the α3-β3 module inducing 
the distortion of the β subunits in response to the rotor (c-ring, γ, δ, ε) motion. 
The proton channel is supposed to be localized in the interface between a and 
c subunits and the translocation is likely achieved by amino acids provided 
with carboxylate groups whose electrostatic interactions drive the rotor [13]. 
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IF1, the endogenous mitochondrial ATP hydrolase inhibitor 
 
In normally respiring mitochondria, the removal of ATP by the adenine 
nucleotide translocase (ANT) ensures that the intra-mitochondrial 
phosphorylation potential is held relatively low while Δψm is high, favouring 
ADP phosphorylation (i.e. ATP synthesis). When mitochondrial homeostasis is 
compromised, the situation can reverse. A decrease in Δψm accompanied by 
an increase in the phosphorylation potential, as glycolysis is upregulated 
together with reversal of the ANT, which imports glycolytic ATP, will favour 
ATP hydrolysis (Fig 6a(i)). 
Therefore, during mitochondrial dysfunction caused by mutations in mtDNA 
genes, the F1Fo-ATPase can run ‘backwards’, acting as an ATP-consuming 
proton pump (Fig 6a(ii)). 
 
 
 
 
 
 
 
 
 
 
 
Figura 5. Role of F1Fo-ATP synthase in mitochondrial bio-energetics. F1Fo-ATP synthase 
activity and co-localisation with IF1 are depicted. (a) Cartoons illustrating the operations of the 
F1Fo-ATP synthase in (i) respiring mitochondria and (ii) mitochondria acting as ATP 
consumers. Panels (b) and (c) illustrate the mitochondrial co-localisation of IF1 (red) with the 
b-subunit of the F1Fo-ATP synthase (green) using immunofluorescence of the HeLa cell line 
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(b) and intact rat kidney (c). DAPI staining of the nuclei is shown in blue. (from Campanella M. 
et al., 2009 Cell Press ) 
 
Although the role of mitochondria in triggering cell death by initiating the 
complex signalling pathways of apoptosis is well deﬁned , it is becoming clear 
that mitochondria could also accelerate progression towards necrotic cell 
death through the simple mechanism of ATP depletion due to ATPase activity 
during mitochondrial dysfunction. This process is limited by an endogenous 
inhibitor protein known as IF1 – the inhibitory factor of the F1Fo-ATPase. 
Since its discovery , a wealth of information has been gathered about the 
biochemical and molecular structure of this small protein, and yet it seems to 
have been remarkably neglected in more physiological studies. The protein 
inhibits ATPase activity in response to acidiﬁcation of the mitochondrial matrix 
, which will usually accompany inhibition of mitochondrial respiration (i.e. 
during hypoxia/ischaemia) and in response to the reversal of F1Fo-ATP 
synthase activity to act as an ATPase [15]. Remarkably, it is known  almost 
nothing about the relative expression levels of the protein in different tissues or 
cell types, or about the physiological impact of varied IF1 expression levels, or 
the mechanisms that regulate its expression. Currently, there are no animal 
models in which the gene is either over-expressed or knocked out; thus, the 
consequences of altered IF1 expression levels for cell or tissue function 
remain unknown. 
Therefore, some recent investigations have set out to explore these issues by 
looking at the functional consequences of varying IF1 expression levels in cell 
lines. These data suggest that IF1 not only inhibits ATPase activity, and so 
protects cells from ATP depletion in response to hypoxia, but also IF1 appears 
to have a role in deﬁning the conformation of the F1Fo -ATP synthase and 
mitochondrial cristae structure, as well as in regulating oxidative 
phosphorylation under normal physiological conditions.  
In 1963, Pullman and Monroy [16] discovered the mitochondrial protein IF1 
(inhibitor factor 1), encoded by the gene ATPIF1. IF1 binds to and inhibits the 
F1Fo-ATPase activity under conditions of both matrix acidiﬁcation  and ATP 
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hydrolysis. The mammalian ATPIF1 gene product contains 106–109 amino 
acids (depending on the species of origin), the ﬁrst 25 amino acids represent a 
mitochondrial targeting presequence that is cleaved within the mitochondria to 
form the mature IF1 protein of 84 amino acids [17]. IF1 is highly conserved 
throughout evolution, with homologues found in birds, nematodes, yeasts and 
plants . This degree of conservation suggests that IF1 is a protein of major 
functional importance. Indeed, structure is sufﬁciently conserved such that IF1 
from one species can inhibit F1Fo -ATPase from another, albeit with varying 
degrees of efﬁcacy . It was recently suggested that IF1 might also localize to 
the plasma membrane where it is presumed to associate with an F1Fo-
ATPase that has also been localized to the plasma membrane. 
 A calmodulin consensus binding motif is present in the middle of the IF1 
protein , and it has been suggested that this motif might dictate its plasma 
membrane localisation in hepatocytes. 
IF1-mediated F1Fo-ATPase inhibition is optimal at a pH of 6.7, a condition 
achieved in the mitochondrial matrix during severe ischaemia. The action of 
IF1 on F1Fo-ATP synthase activity, however, remains poorly documented in 
the literature. Given the requirement for an electrochemical potential, this 
partly reﬂects the technical difﬁculties involved in the study of F1Fo-ATP 
synthase activity in contrast with relatively straightforward measurements of 
ATP hydrolysis. Although some evidence suggests that IF1 can inhibit 
synthase activity, the importance of these observations remains unclear. 
The detailed crystal structure of IF1-inhibited F1-ATPase has been solved, 
revealing two main features [18-19]. First, IF1 acts as a homodimer, 
simultaneously inhibiting two F1-ATPase units  and, second, residues in the 
two protein complexes form numerous associations that involve several F1-
ATPase subunits. Full association of IF1 with the F1Fo-ATPase is thought to 
occur only during ATP hydrolysis. Gledhillet al.  suggest that low-afﬁnity 
binding of IF1 to the surface of the F1 domain might occur  even in the ground 
state; however, the functional consequence of this activity is not clear. 
Dimerization of IF1 promotes dimerization of the F1-ATPase during ATP 
hydrolysis as demonstrated either using blue native gel electrophoresis or in 
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the IF1-inhibited F1-ATPase crystal structure. It has been suggested that 
dimerization of the IF1-inhibited ATPase structure could help to stabilize the 
complex against the torque induced by ATP hydrolysis in the F1 domain, or it 
might bring the F1-ATPase domains sufﬁciently close together (100 A˚) that 
they hinder each others’ rotation. Dimerization of yeast F1Fo-ATP synthase 
occurs independently of IF1 [20] .  
 
 
IF1 cell biology: functional consequences of altered 
expression 
 
The functional consequences of genetic manipulation of IF1 protein levels 
were recently explored in cell lines (HeLa cells and muscle-derived C2C12 
cells) [21], in which IF1 was either overexpressed by transient transfection or 
knocked down using small interfering RNA (siRNA). 
Two approaches were used to assay IF1-mediated inhibition of F1Fo -ATPase 
activity: (i) measurements of the rate of ATP depletion after inhibition of 
oxidative phosphorylation and glycolysis (halting all ATP synthesis) to assess 
ATP hydrolysis by the F1Fo-ATPase; and (ii) measurements of  Δψm in the 
face of inhibition of oxidative phosphorylation to assess the proton pumping 
activity of the F1Fo-ATPase. 
In the ﬁrst of these assays, cellular ATP synthesis was completely inhibited 
using either (i) iodoacetic acid (IAA) to inhibit glycolysis together with sodium 
cyanide (CN-) to inhibit mitochondrial respiration, or (ii) IAA to inhibit glycolysis 
and oligomycin to inhibit oxidative phosphorylation. After inhibition of all 
cellular ATP synthesis, the rate of ATP depletion reﬂects the activity of all 
active ATP consuming processes in the cell. When oxidative phosphorylation 
is inhibited with CN-, the F1Fo-ATPase activity contributes to the global rate of 
ATP consumption. 
By contrast, when oxidative phosphorylation is inhibited with oligomycin, the 
F1Fo-ATPase activity cannot contribute to ATP consumption. The difference 
between the two rates therefore gives a measure of the speciﬁc contribution of 
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the F1Fo-ATPase as an ATP consumer. The concentration of free intracellular 
magnesium ([Mg2+]c) increases as an index of ATP consumption as Mg2+ is 
released upon ATP hydrolysis. This provides a useful assay at the level of 
single cells, where direct measurements of [ATP] are not really practical  [20]. 
After complete ATP depletion, cells underwent lysis; this occurred between 45 
and 75 min in HeLa cells. In cells lacking IF1, the initial rate of ATP 
consumption was signiﬁcantly faster in the presence of CN- and IAA, and the 
time to lysis was signiﬁcantly shorter compared with wild-type cells (grey 
versus black; Figure 2). In the presence of oligomycin and IAA, the rate of ATP 
consumption was slower and the time to lysis in wild-type cells was 
substantially delayed (red trace; Figure 2), indicating the overall ATP-
consuming activity of the F1Fo -ATPase. Together, these experiments show 
that endogenous IF1 functionally inhibits ATPase activity in intact cells. Similar 
to the protection of rat cardiomyocytes against contracture, this experiment 
demonstrates that inhibition of F1Fo-ATPase activity is protective to cells. This 
is consistent with the ﬁnding that IF1 overexpression signiﬁcantly reduced cell 
death in response to oxygen and glucose deprivation [22]. 
In a schematic cartoon (Figure 2b) we have illustrated the predicted impact of 
IF1 on changes in [ATP] and during the progression of a period of ischaemia. 
In cells with levels of IF1 sufﬁcient to completely inhibit the ATPase activity 
(equivalent to the action of oligomycin),  Δψm collapses rapidly as soon as the 
respiratory chain is inhibited, whereas [ATP] can be preserved for a 
considerable period of time until other ATP consumers drive ATP depletion. 
This timing will vary depending on the glycolytic capacity of the cell type and 
the activity of the ATP consumers. In marked contrast, in cells in which IF1 is 
absent, Δψm can be maintained at a new steady state for prolonged periods of 
time, but this occurs at the expense of cellular ATP, which becomes depleted 
more quickly. Once ATP is depleted, Δψm will collapse as there is no ATP left 
as a substrate for the F1Fo- ATPase  [23]. 
These principles are readily established experimentally. Thus, CN- inhibits 
electron transfer along the electron transport chain and hence its proton-
pumping capacity, leading to depolarisation of mitochondria. Recently, the  
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extent of mitochondrial depolarisation in HeLa cells overexpressing IF1 was 
shown to be greater than that seen in wild-type cells. Conversely, when IF1 
expression was suppressed, Δψm was maintained at a new steady state for
 
prolonged periods of time. These experiments are more revealing than they 
might initially seem as they show that endogenous IF1 protein is not 
necessarily expressed with a ﬁxed stoichiometry in relation to the F1Fo -ATP 
synthase. That activity can be increased or decreased by genetic 
manipulations argues that there is room for regulation of expression of this 
protein in relation to that of the F1Fo protein complex. This idea is 
strengthened by several observations. In central nervous system cultures 
containing both astrocytes and neurons, immunoﬂuorescence measurements 
showed that ratios between the expression levels ofthe F1Fo-ATP synthase b-
subunit and IF1 protein levels varied dramatically between the two cell types. 
Neurons,with a relatively low b-subunit:IF1 ratio, exhibited rapid loss of Δψm in 
response to CN-, whereas astrocytes, with high b-subunit:IF1 ratio, maintained 
Δψm, albeit at a
 reduced level [20]. 
F1Fo-ATPase activity was clearly required for the maintenance of Δψm 
because treatment of astrocytes with oligomycin caused rapid mitochondrial 
depolarization. 
 
 
 
Reactive Oxygen Species 
 
Reactive oxygen species (ROS) and the cellular redox state are increasingly 
thought to be responsible for affecting different biological signaling pathways. 
ROS are formed from the reduction of molecular oxygen or by oxidation of 
water to yield products such as superoxide anion (O2 • −), hydrogen peroxide 
(H2O2), and hydroxyl radical (•OH). 
In a biological system, the mitochondria and NAD(P)H oxidase are the major 
sources of ROS production. In moderate amounts, ROS are involved in a 
number of physiological processes that produce desired cellular responses. 
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However, large quantities of ROS in a biological system can lead to cellular 
damage of lipids, membranes, proteins,and DNA. Nitric oxide (NO•) is another 
contributor to ROS concentration and the formation of reactive nitrogen 
intermediates (RNIs).  NO• is generated by specific nitric oxide synthases that 
also contribute to a large number of physiological processes. NO• can react 
with superoxide to form a potent oxidizing agent, peroxynitrite (ONOO−), which 
contributes to cellular damage and oxidative stress. 
Oxidative stress results from overproduction of ROS and/or decreased system 
efficiency of scavengers such as vitamin C, vitamin E, and glutathione. 
The direction of many cellular processes, such as phosphorylation and 
dephosphorylation and regulation of the cell cycle, can be determined by the 
redox state. Increases in ROS can lead to an imbalance of the cellular 
oxidation state, disrupting the redox balance. The intracellular ROS 
concentration can be estimated using the redox potential, E. A cell contains 
many biological redox couples, such as NADP+/NADPH and GSSG/2GSH, 
which allow the cell to maintain redox homeostasis. NADPH has the lowest 
reduction potential and thus serves as the driving force for other redox 
couples. GSSH/GSH is the main redox buffer of the cell and is found 
throughout all cellular compartments. The addition of oxidants to a cell system 
results in an increased [GSSG]/[GSH] ratio, thereby increasing the value of E 
above a specific threshold, which is representative of an oxidative state.  
Mitochondria are major sources of reactive oxygen species; the main sites of 
superoxide radical production in the respiratory chain are Complexes III and I, 
with a general consensus that production at Complex I is about half of that at 
Complex III; however, other mitochondrial enzymes,such as Complex II, 
glycerol-1-phosphate dehydrogenase, and dihydroorotate dehydrogenase, are 
also involved in production of ROS. 
ETC works basically with one-electron transfer steps and the redox centers 
present in oxphos complexes can potentially transfer electrons to molecular 
oxygen. ROS production in mitochondria depends mainly on both oxygen 
concentration and redox status of ETC complexes, and in physiological 
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conditions both parameters are actually determined by tissue metabolic 
requirements. 
Since the structure of Complex I is not completely known, the site of electron 
leak has not been located and all major cofactors have been proposed as site 
of oxygen reduction: FMN, iron-sulfur clusters N2 and N1a and the 
semiquinone radical formed upon ubiquinone reduction [24-25]. However, the 
electron leak from one or more of these sites results in superoxide anion 
radicals (O2•-) production in the matrix. 
One-electron reduction of oxygen in Complex III is accomplished by 
ubisemiquinone and increases in presence of antimycin, an inhibitor that binds 
one of the CoQ reduction sites; the release of superoxide anion from Complex 
III may occur on both side of inner membrane [26].  
Anion superoxide production by Complex I reaches its maximal rate during 
reverse electron transfer (RET), wich occurs when electron supply, i.e. from 
succinate, reduces CoQ that in presence of a significant high ΔP could give 
electrons back to Complex I leading to formation of NADH from NAD+ through 
FMN; the role of Complex I in this process has been confirmed by use of 
rotenone. The RET-associated superoxide production is deeply dependent on 
ΔP since it could be completely abolished by even small decreases in the 
proton electrochemical potential achieved through addition of ADP or 
uncoupler [27].  
Increase in Complex I prosthetic groups reduction may also occurs in 
presence of increased NADH/NAD+ ratio that may arise when respiratory 
chain activity is inhibited [28]. 
Thus, it is clear that alterations either in Complex I activity and structure or in 
the whole oxphos system might likely lead to an overproduction of ROS that 
could reflect in a non-reversible oxidative modification of lipids, proteins and 
nucleic acids. Although it has been demonstrated that inhibition threshold for 
Complex I (30%) or Complex III (70%) must be reached before to observe a 
significant ROS production, in a context of partial energetic impairment due to 
mutations in mtDNA genome also minimal shifts in the redox equilibrium might 
represent a further input of stress for the cell [28]. 
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Because of the potential deleterious effect of a natural by-product of 
mitochondrial metabolism aerobic cells evolved efficient systems for ROS 
scavenging. The ROS-scavenging system must be highly regulated to rapidly 
answer to even slight changes in the redox state of cell. Since all genes 
implied in maintaining the correct balance between ROS production and 
scavenging are nuclear encoded, a proper mitochondria-nucleus cross-talk is 
of primary importance to counteract oxidative stress risk. 
Superoxide dismutase catalyzes dismutation of superoxide anion in hydrogen 
peroxide. In mammalian three genes encoding superoxide dismutases with 
different localization have been found. SOD1 and SOD3 encode two enzymes 
containing copper and zinc in their catalytic site (CuZnSOD) but showing 
different localization: SOD1 product is localized in cytoplasm, nuclear 
compartments, mitochondrial intermembrane space and lysosomes of 
mammalian cells while SOD3 product exists as a homotetramer and is located 
in the extracellular environment. The expression pattern of SOD3 is highly 
restricted to specific cell type and tissues where its activity can exceed that of 
SOD1 and SOD2. A third isoform of SODs has manganese as a cofactor 
(MnSOD) and is localized in mitochondrial matrix of aerobic cells where it is 
active in the tetrameric form [29]. 
Glutathione peroxidase (GPX) contains selenium in the catalytic site and 
catalyzes reduction of hydrogen peroxide by glutathione; different isoforms are 
present in cytoplasm and mitochondria and are differently expressed 
depending on tissues [30].  
Peroxiredoxins (Prdx) are thiol-dependent enzymes working as hydrogen 
peroxide scavenger; isoform 3 is exclusively localized in mitochondrial matrix. 
Catalase catalyzes hydrogen peroxide conversion in H2O and O2, is a 
tetramer containing heme as prosthetic group and is localized in peroxisomes, 
in cytosol and in heart mitochondria [1]. 
Non-enzymatic systems like glutathione, thioredoxines and vitamins (E, C) 
which can participate to catalytic action of antioxidant enzymes as cofactors, 
are as well fundamental in maintaining the balance in the redox state of cells. 
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Intracellular ROS originate from multiple sites, including the mitochondrial 
electron transport chain, cytochrome P-450 oxygenase, xanthine oxidase 
(XO), lipoxygenase, cyclooxygenase, and uncoupled nitric oxide (NO) 
synthase (NOS). NADPH oxidase, a prominent source of ROS in vascular 
tissue, has several isoforms localized to different sites within the cell. NADPH 
oxidase that contains the NOX2 catalytic subunit can be plasmalemmal bound 
and produce O2·extracellularly or within the cytosol. The extracellularly 
generated O2· can reenter the cell through anion-selective chloride channel-3 
channels or by conversion to H2O2 via extracellular SOD [31].  
The NOX4 containing oxidase is located in endosomes , focal adhesions, and 
nuclei  and generates O2· intracellularly. Other members of the NOX family 
include NOX1, which can be found in various subcellular localizations such as 
nuclei and caveolae, NOX3 and NOX5, which both have been shown to 
colocalize with the plasma membrane. 
Thus subcellular localization of NADPH oxidase allows for stereospeciﬁc 
release of O2·, which is spontaneously or catalytically (SOD) converted to 
H2O2, the primary signaling ROS. As an uncharged molecule, H2O2 can 
traverse cell membranes, is rapidly inactivated by endogenous catalase and 
peroxiredoxins, and can reversibly alter enzyme function through oxidative 
modiﬁcation of susceptible residues, including arginine, cysteine, histidine, and 
others. These properties strongly support a signaling role for intermediate 
doses of H2O2.  Signaling dose ranges for H2O2 were established in human 
and animal models and vary from 1 µM to 10 mM. Interestingly, in rat coronary 
arterioles, sensitivity to H2O2 is increased with aging [32]. 
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2 Oxygen Sensing and Homeostasis 
 
The survival of all metazoan organisms is dependent on the regulation of O2 
delivery and utilization to maintain a balance between the generation of energy 
and production of potentially toxic oxidants. 
About 1.5 billion years ago eukaryotic organisms appeared containing 
mitochondria, sub cellular organelles in which glucose is oxidized to carbon 
dioxide and water, thereby completing the energy cycle. Reducing equivalents 
are generated that pass through the mitochondrial respiratory complex, which 
results in the formation of a proton gradient that is used to drive the synthesis 
of adenosine 5′-triphosphate. 
Humans have evolved complex circulatory, respiratory, and neuroendocrine 
systems to ensure that oxygen levels are precisely maintained, since an 
excess or deficiency may result in the death of cells, tissue, or the organism. 
Oxygen homeostasis represents an organizing principle for understanding 
evolution, development, physiology, and disease. Historically, oxygen sensing 
was thought to be limited to specialized cells, such as the glomus cells of the 
carotid body, which depolarize within milliseconds in response to hyperoxia by 
means of incompletely understood mechanisms. We now recognize that all 
nucleated cells in the body sense and respond to hypoxia. 
Under conditions of reduced oxygen availability, hypoxia-inducible factor 1 
(HIF-1) regulates the expression of genes that mediate adaptive responses. In 
hypoxic cells, the transcription of several hundred messenger RNAs (mRNAs) 
is increased, and the expression of an equal number of mRNAs is decreased. 
The changes are dependent on HIF-1 in both cases, but HIF-1 binding is 
detected only at genes with increased expression. HIF-1 decreases mRNA 
expression indirectly by regulating transcriptional repressors and microRNAs. 
HIF-1 was first identified in human cells as a regulator of erythropoietin, the 
hormone that controls red-cell production; vascular endothelial growth factor 
(VEGF), which stimulates angiogenesis; and glycolytic enzymes, which adapt 
cell metabolism to hypoxic conditions oxygen sensing, gene expression, and 
adaptive responses to hypoxia)[33]. 
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Mechanism of HIF-1 Activation 
 
Active HIF-1 is a heterodimer composed of a constitutively produced HIF-1β 
subunit, which is stable irrespective of the oxygen level, and a labile HIF-1α 
subunit.  Canonically, it is assumed that regulation of HIF-1α is indeed the 
critical event implicated in the HIF-mediated cellular response to low oxygen, 
as HIF-1α is highly induced by hypoxia [33-34]. The HIF-1α subunit is virtually 
undetectable under normoxic conditions, since it is rapidly degraded by the 
ubiquitin–proteasome pathway. 
Under normoxic conditions (Fig 7A), HIF-1α has a very short half-life of less 
than 5 min, being continuously synthetized and degraded [35]. It is well 
established that under normal oxygen levels, HIF-1α is hydroxylated on proline 
residues 402 and 564 in the oxygen-dependent degradation domain by 
specific prolyl hydroxylases (PHDs) [36] that require oxygen and 2- 
oxoglutarate, as co-substrates, and iron (Fe2+) and ascorbate, as co-factors. 
The use of iron by these enzymes explains the hypoxia-mimetic effects of iron 
antagonists and chelators, such as desferrioxamine (DFO) and cobalt chloride 
[37].  
Although 2-oxoglutarate, a tricarboxylic acid (TCA) cycle intermediate, is 
essential for the activity of PHDs because of its role in the coordination of iron 
in the catalytic core, other TCA cycle intermediates such as succinate and 
fumarate appear to inhibit PHDs by competing with 2-oxoglutarate for binding 
to the active site. Once hydroxylated, HIF-1α is recognised by the von Hippel–
Lindau protein (VHL), which is part of an ubiquitin ligase complex known as E3 
ligase complex that targets HIF-1α for polyubiquitination and subsequent 
proteasomal degradation. In addition to VHL, the E3 ligase complex is formed 
by the RING-finger protein RBX1, which is thought to recognise a cognate E2, 
as well as several adaptor proteins, such as elongin B, elongin C and cullin 2 
[38]. The asparagine 803 residue of HIF-1α is also hydroxylated under 
normoxic conditions by a specific asparagine hydroxylase named factor-
inhibiting HIF-1 (FIH-1), which impairs the interaction of the transcriptional co-
activators p300/CREB binding protein (CBP) with the HIF-1α C-terminal 
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transactivation domain. This leads to further repression of the transcriptional 
activity of HIF-1. Like PHDs, FIH-1 requires 2-oxoglutarate, iron, ascorbate 
and dioxygen to induce hydroxylation; however, as opposed to PHDs, FIH-1 is 
not inhibited by intermediates of the TCA cycle. 
When oxygen becomes limited (Fig 7B), the proline residues are no longer 
hydroxylated and HIF-1α escapes degradation, accumulating in the cell. 
Subsequently, HIF-1α is translocated into the nucleus, where it dimerises with 
HIF-1β and binds to a core pentanucleotide sequence (5′-RCGTG-3′) in 
hypoxia-responsive elements of the promoter or enhancer sequences of target 
genes. Ultimately, HIF-1 activates the expression of numerous genes that help 
cells to survive at low oxygen levels. In addition, p300/CBP interact with HIF-
1α, due to inhibition of Asn803 hydroxylation, increasing the transcriptional 
activity of HIF-1 [35]. 
Hypoxic responses are also mediated by HIF-2, a heterodimer composed of 
HIF-1β and HIF-2α (a paralogue of HIF-1α that is also regulated by oxygen-
dependent hydroxylation). HIF-1α is present in all nucleated cells of all 
metazoan species, whereas HIF-2α expression is restricted to certain cell 
types within vertebrate species and plays an important role in both 
erythropoiesis and vascularization. Another paralogue, HIF-3α, appears to 
function as an inhibitor of HIF-1a [39]. 
Establishing the specific roles of HIF-1a, HIF-2a, and HIF-3a in oxygen 
homeostasis is a major challenge of current research [40]. 
HIF-1α−/− mouse embryos, which lack HIF-1α, are arrested in their 
development at midgestation and die from cardiac and vascular defects and 
decreased erythropoiesis, indicating that all three components of the 
circulatory system are dependent on HIF-1 for normal development.  
PDH1 and PHD3 also hydroxylate HIF-1a when overexpressed, but their 
physiological functions have not been established. PHD2 activity is reduced 
under hypoxic conditions either as a result of substrate limitation or as a result  
of  inhibition of the catalytic center [which contains Fe(II)] by ROS generated at 
complex III of the mitochondrial respiratory chain [41].  
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ROS levels increase in response to hyperoxia, but HIF-1a levels do not, which 
suggests that the site of ROS generation may be different in hyperoxic cells or 
that ROS generation by complex III is necessary, but not sufficient, to induce 
HIF-1a under hypoxic conditions. FIH-1 (factor inhibiting HIF-1) is another 
dioxygenase that hydroxylates asparagine residue 803 of HIF-1a and, 
thereby,blocks its interaction with the coactivator p300. The half-life of HIF-1a 
is also regulated in an O2-independent manner by the competitive binding of 
either heat shock protein HSP90, which stabilizes the protein, or RACK1, 
which interacts with Elongin C and, thereby, promotes HIF-1a ubiquitination 
and degradation that is independent of PHD2 and VHL . A second major O2-
independent regulatory mechanismis the stimulation of HIF-1a protein 
synthesis by signal transduction via phosphatidylinositol 3-kinase, protein 
kinase B (AKT), and mammalian target of rapamycin [33]. 
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Figura 6. In well-oxygenated cells (Panel A), prolyl hydroxylase domain 2 (PHD2) uses 
oxygen to hydroxylate hypoxia-inducible factor 1 (HIF-1α) on a proline residue (Pro–OH). The 
von Hippel–Lindau (VHL) protein binds to HIF-1α containing Pro–OH and recruits a ubiquitin 
E3 ligase. The polyubiquitination of HIF-1α flags the protein for degradation by the 26S 
proteasome. Factor inhibiting HIF-1 (FIH-1) also uses oxygen to hydroxylate HIF-1α on an 
asparagine residue (Asn–OH). HIF-1α containing Asn–OH cannot be bound by the coactivator 
protein p300, thereby preventing HIF-1α from activating gene transcription. Under hypoxic 
conditions (Panel B), the Pro and Asn hydroxylation reactions are inhibited, and HIF-α (i.e., 
either HIF-1α or HIF-2α) rapidly accumulates, dimerizes with HIF-1β, recruits p300, binds to 
hypoxia response elements, and activates the transcription by RNA polymerase II (Pol II) of 
hundreds of target genes, such as the following: EPO, encoding 
erythropoietin(photomicrograph at top); VEGF, encoding vascular endothelial growth factor, 
(angiogram in middle); and PDK1, encoding pyruvate dehydrogenase kinase 1, which inhibits 
the conversion of pyruvate to acetyl coenzyme A for oxidation in the mitochondrion (electron 
micrograph at bottom). (from Semenza GL., 2011 N. Engl. J Med) 
 
 
 
Regulation of cellular metabolism by HIF-1 α 
 
Even the simple roundworm Caenorhabditis elegans, which consists of about 
1000 cells and contains no specialized systems for oxygen delivery, expresses 
HIF-1, indicating that the primordial function of HIF-1 was to mediate adaptive 
responses that allow cells to survive oxygen deprivation. One way in which 
HIF-1 promotes cell survival under hypoxic conditions is by mediating a switch 
from oxidative to glycolytic metabolism. The glycolytic enzymes convert 
glucose to pyruvate, which can be converted either to acetyl coenzyme A 
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(CoA) for oxidation in the tricarboxylic acid cycle or to lactate as a glycolytic 
end product (Fig. 8). HIF-1 activates the expression of lactate dehydrogenase 
A and pyruvate dehydrogenase kinase 1 (PDK1), thus tipping the balance from 
oxidative to glycolytic metabolism [39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 7. Regulation of Glucose Metabolism in Response to Changes in Cellular Oxygen 
Levels. Glucose is converted to pyruvate by the action of the glycolytic enzymes.  In well-
oxygenated cells (red pathway), pyruvate dehydrogenase (PDH) converts  pyruvate to acetyl 
coenzyme A (CoA), which is oxidized in the mitochondrial tricarboxylic acid (TCA) cycle, 
generating electrons that are transported through a series of protein complexes (ETC) and are 
eventually transferred to oxygen to form water. The proton gradient established by the ETC is 
used to synthesize ATP. Under hypoxic conditions (blue pathway), pyruvate dehydrogenase 
kinase 1 (PDK1) inactivates PDH, and lactate dehydrogenase A (LDHA) converts pyruvate to 
lactate. The expression of the glycolytic enzymes is also induced to increase flux through the 
pathway 
 
 
As compared with glycolysis, oxidative metabolism yields 18 times as much 
ATP per mole of glucose consumed. Although it is the conventional wisdom 
that cells respire until oxygen is depleted, at which point they switch to 
glycolysis, it is  known  that this model of metabolic regulation is incorrect. HIF-
1α−/− fibroblasts are incapable of switching from oxidative to glycolytic 
metabolism when shifted from aerobic conditions of 95% air and 5% carbon 
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dioxide (20% oxygen, with a partial pressure of oxygen [PO2] of about 140 mm 
Hg) to hypoxic conditions (1% oxygen, with a PO2 of about 7 mm Hg). 
ATP levels are higher in HIF-1α−/− cells at 1% oxygen than in HIF-1α+/+ cells 
at 20% oxygen, indicating that 1% oxygen does not limit ATP production. 
However, HIF-1α−/− fibroblasts maintained at 1% oxygen or less will die owing 
to toxic levels of reactive oxygen species [42].  
HIF-1 plays three critical roles in the hypoxia-induced metabolic switch from 
oxidative to glycolytic metabolism. HIF-1 induces expression of: (1) upstream 
glucose transporters and glycolytic enzymes to increase flux from glucose to 
pyruvate; (2) PDK1 to block the conversion of pyruvate to acetyl CoA; and (3) 
lactate dehydrogenase A to convert pyruvate to lactate (Fig 9). 
Under aerobic conditions, electrons are transferred from NADH and flavin 
adenine dinucleotide (FADH2) (generated by oxidation of acetyl CoA) to 
mitochondrial complex I or II, then to complex III, and finally to complex IV, 
where they react with oxygen to form water. Under hypoxic conditions, the 
release of electrons is increased before the transfer to complex IV, resulting in 
the formation of superoxide, which is then converted to hydrogen peroxide and 
other toxic reactive oxygen species. Thus, there is sufficient oxygen for 
oxidative phosphorylation to occur in hypoxic fibroblasts, but at the cost of a 
loss of redox homeostasis [43]. 
The extent to which these findings apply to disease states, such as cancer and 
pulmonary hypertension, remains to be determined. 
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Figura 9. Regulation of hypoxia-induced metabolic switches by HIF-1. In hypoxic cells, 
HIF-1 stimulates increased glycolytic ﬂux to pyruvate (1) and its reduction to lactate (2).In 
addition, HIF-1-induced PDK1 activity inhibits PDH (3), resulting in decreased ﬂux through the 
TCA cycle. The resulting attenuation of oxidative phosphorylation is essential to prevent the 
generation of reactive oxygen species (ROS) resulting from ineffective electron transport 
under hypoxic conditions. HIF-1 mediates these effects through transcriptional activation of 
genes encoding glucosetransporters and glycolytic enzymes (1), lactate dehydrogenase A (2), 
and PDK1 (3). (from Kim JW et al., Cell Metabolism, 2006) 
 
 
Effects of hypoxia on mitochondrial OXPHOS complexes 
 
Oxygen is the terminal acceptor of electrons from cytochrome c oxidase, which 
has a very high affinity for it, being the oxygen concentration for half-maximal 
rate at pH 7.4 approxymately 0.7 µM [44]. 
It has been showed that the rate of O2 consumption is not dependent on 
oxygen concentration up to 20 µM at pH 7.0. Thus, it has been found that the 
rate of O2 consumption remained constant until [O2] fell below 15 µM  [45] 
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Most reports in the literature consider hypoxic conditions occurring in cells at 
5-0.5% O2, 
corresponding to a concentration of 46-4.6 µM in the cells culture medium. 
During hypoxia, a number of changes on the OXPHOS machinery 
components, mostly mediated by HIF-1 have been found. 
Kim et al., revealed that adaptation to hypoxia critically depends on the active 
inhibition of mitochondrial pyruvate metabolism and respiration. 
HIF-1 actively suppresses metabolism through the tricarboxylic acid cycle 
(TCA) by directly trans-activating the gene encoding pyruvate dehydrogenase 
kinase 1 (PDK1). PDK1 inactivates the TCA cycle enzyme, pyruvate 
dehydrogenase (PDH), which converts pyruvate to acetyl-CoA. Forced PDK1 
expression in hypoxic HIF-1a null cells increases ATP levels, attenuates 
hypoxic ROS generation, and rescues these cells from hypoxia-induced 
apoptosis. These studies reveal a hypoxia-induced metabolic switch that 
shunts glucose metabolites from the mitochondria to glycolysis to maintain 
ATP production and to prevent toxic ROS production (Fig. 6). 
Moreover, HIF-1 is responsible of the regulation of COX activity.  COX, which 
is located in the mitochondrial inner membrane, is a dimer in which each 
monomer consists of 13 subunits. Subunits I, II and III (COX1–COX3 
respectively),which are encoded by the mitochondrial genome and constitute 
the catalytic core of the enzyme, are highly conserved in all eukaryotes. The 
high-resolution crystal structure of bovine COX revealed that subunit IV 
(COX4) interacts, via its transmembrane domain, with COX1 and, via its C-
terminal hydrophilic domain, with COX2. COX4 binds ATP, leading to allosteric 
inhibition of COX activity at high ATP/ADP ratios. 
Mammalian cells express a predominant COX4-1 isoform, whereas an 
alternative COX4-2 isoform is also expressed in certain tissues. However, 
neither the molecular mechanisms regulating expression of the COX4/1 and 
COX4/2 genes that encode these proteins, nor the functional signiﬁcance of 
alternative isoforms, was known. Analysis of cultured mouse and human cells 
revealed that COX4-2 mRNA and protein expression were induced by hypoxia. 
HIF-1 heterodimers containing HIF-1β and either HIF-1α or HIF-2α bound to 
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hypoxia response elements located in the 5’-ﬂanking region and ﬁrst intron of 
the COX4/2 gene within nuclear chromatin of human cells cultured under 
hypoxic conditions [33]. 
Analysis of the effects of gain-of-function, loss-of-function and loss-of-function-
with-subunit-rescue experiments for COX4-1 and COX4-2 revealed that the 
regulated expression of these subunits optimized the efﬁciency of respiration 
in human cells under aerobic and hypoxic conditions respectively [46].  
When COX4-2 was replaced by COX4-1, there were signiﬁcant decreases in 
O2 consumption, COX activity and ATP concentration under hypoxic 
conditions. When COX4-2 replaced COX4-1 under non-hypoxic conditions, O2 
consumption, COX activity and ATP concentration were maintained at normal 
levels, but at the cost of increased ROS production and caspase activation. 
Taken together, the results of these experiments indicate that the COX4 
subunit switch constitutes a critical adaptive response of mammalian cells to 
hypoxia [33]. 
According with the evidence of Zhang et al., the respiration rate decrease has 
to be ascribed to mitochondrial autophagy, due to HIF-1-mediated expression 
of BNIP3. This interpretation is in line with preliminary results obtained by 
Solaini et al.,  where the assay of the citrate synthase activity of cells exposed 
to different oxygen tensions was performed and it  indicated that the citrate 
synthase activity, which is taken as an index of the mitochondrial mass, and 
Oxygen levels are directly linked [44]. 
Zhang et al., found that mitochondrial autophagy is an adaptive metabolic 
response that promotes the survival of cells under conditions of prolonged 
hypoxia. This process requires the HIF-1-dependent induction of BNIP3 and 
the autophagy machinery as demonstrated by Beclin-1 and Atg5 loss-of 
function studies and the assessment of GFP-LC3 protein subcellular 
localization. Furthermore, they demonstrate that HIF-1 regulates mitochondrial 
mass under normal physiological conditions, as even partial deficiency of HIF-
1 α had a profound effect on BNIP3 expression and mitochondrial mass in the 
lungs of mice exposed to room air [47]. 
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Hypoxia alters the expression of hundreds of mRNAs required for many 
aspects of tumorigenesis, and the HIF transcription factors play a central role 
in this response. 
Recently, the effect of hypoxia on microRNA expression was reported.  
microRNAs  are a novel class of gene modulators that can each regulate as  
many as several hundred genes with spatial and temporal specificity. These 
non-coding RNAs have been proposed to  contribute to oncogenesis by 
functioning either as tumor suppressors (e.g., miR-15a/miR16-1) or oncogenes 
(e.g., miR-155 and the miR-17-92 cluster). 
Recently, it has been showed that moderate hypoxia decreases oxygen 
consumption and Complex I activity via the HIF-1-dependent upregulation of 
NDUFA4L2. This demonstrate that NDUFA4L2 is a HIF-1-dependent gene, 
emphasizing the role of HIF-1 in mitochondrial reprogramming and revealing 
NDUFA4L2 as an important element in metabolic adaptation to hypoxia. 
PDKs could potentially cooperate with NDUFA4L2 to reduce mitochondrial 
Complex I activity under moderate hypoxic conditions, but it is also 
conceivable that NDUFA4L2 has other biological functions that cannot be 
accomplished by PDKs. For example, when metabolites that fuel the TCA 
cycle originate from pathways different from glycolysis (e.g., glutaminolysis or 
fatty acid oxidation), it would be necessary to reduce ETC activity in order to 
decrease mitochondrial function  [48].  
Hypoxia-induced NDUFA4L2 expression could fulﬁll this role, reducing oxygen 
consumption due to its strategic position downstream of the TCA cycle, 
possibly at Complex I. Likewise, hypoxia induces the upregulation of 
microRNA-210, which represses 
ISCU1/2 [49-51]. These proteins facilitate the assembly of iron-sulfur clusters, 
including those in Complex I, Complex III, and aconitase, which are critical for 
electron transport and mitochondrial redox reactions. As a result, microRNA-
210 represses mitochondrial respiration. In HeLa cells and in Human Umbilical 
Vein Endothelial Cells (HUVEC), ISCU1/2 protein does not decrease prior to 
48 hr and only under 0.5% O2, while NDUFA4L2 becomes functional as early 
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as 24 hr at 1% O2. Moreover, ISCU1/2 recovery in hypoxic HeLa cells did not 
disturb proliferation. In summary [48]. 
As mentioned above in this thesis, the F1F0 ATPase (ATP synthase) is the 
enzyme responsible of catalysing ADP phosphorylation as the last step of 
OXPHOS. It is a rotary motor using the proton motive force across the 
mitochondrial inner membrane to drive the synthesis of ATP. It is a reversible 
enzyme with ATP synthesis or hydrolysis taking place in the F1 sector at the 
matrix side of the membrane, chemical catalysis being coupled to H+ transport 
through the transmembrane F0 sector. IF1 protein binds to  the catalytic F1 
sector at low pH and low Δψm (such as it occurs in hypoxia/ischemia). IF1 
appears to be associated with ROS production and mitochondrial autophagy 
(mitophagy). This is a mechanism involving the catabolic degradation of 
macromolecules and organelles via the lysosomal pathway that contributes to 
housekeeping and regenerate metabolites. Autophagic degradation is involved 
in the regulation of the ageing process and in several human diseases, such 
as myocardial ischemia/reperfusion, Alzheimer's Disease, Huntington 
diseases, and inflammatory diseases and, it promotes cell survival by reducing 
ROS and mtDNA damage under hypoxic conditions [44]. 
Campanella [20], reported that, in HeLa cells under normoxic conditions, basal 
autophagic activity varies in relation to the expression levels of IF1. 
Accordingly, cells overexpressing IF1 result in ROS production similar to 
controls, conversely cells in which IF1 expression is suppressed show an 
enhanced ROS production. In parallel, the latter cells show activation of the 
mitophagy pathway, therefore 
suggesting that variations in IF1 expression level may play a significant role in 
defining two particularly important parameters in the context of the current 
review: rates of ROS generation and mitophagy. 
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Effects of hypoxia on mitochondrial structures and dynamics 
 
Mitochondria form a highly dynamic tubular network, the morphology of which 
is regulated by frequent fission and fusion events [44].  
In most cell types mitochondria form a reticular network or several such 
networks with additional solitary small tubular remnants, mostly resulting from 
fission of the central mitochondrial reticulum. 
Electron tomography revealed details of the internal structure  and established 
that cristae, visualized previously by 2 Delectron microscopy, represent sacks 
protruding deeply into the central matrix space of the mitochondrial tubules. 
Consequently, the major morphology features of a mitochondrion can be 
distinguished, such as the outer membrane (OM), topologically contouring the 
tubular surface; the inner membrane (IM), with its peripheral IM part termed 
inner boundary membrane (IBM) and intracristae parts (ICM); the 
intermembrane space, with its peripheral part (PIMS), located between OM 
and IBM, and the intracristae part (cristae sacks interiors, ICS); finally, the 
matrix filling the IM-engulfed space [52]. 
Apart from its role in filtering incoming molecules by porin/VDAC channels, the 
OM represents an external “information keyboard” or a “switchboard”, where 
the integrative response of the BCL-family and other information proteins 
triggers induction or inhibition of various cellular processes, such as apoptosis, 
autophagy, and mitoptosis. At the OM, the information responses are also 
integrated with the activities of the major GTPase proteins, thereafter called 
mitodynamins, which dynamically affect shape-forming of the mitochondrial 
reticular network. In this way, mitodynamins specifically participate in cell 
death processes, whereas the BCL-family proteins BAX and BAK play a role in 
shaping of the mitochondrial network [52]. 
The fusion/fission machineries are modulated in response to changes in the 
metabolic conditions of the cell, therefore one should expect that hypoxia 
affect mitochondrial dynamics. Oxygen availability to cells decreases glucose 
oxidation, whereas oxygen shortage consumes glucose faster in an attempt to 
produce ATP via the less efficient anaerobic glycolysis to lactate (Pasteur 
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effect). Under these conditions, mitochondria are not fueled with substrates 
(acetyl-CoA and O2), inducing major changes of structure, function, and 
dynamics. However, the direct regulation of mitodynamins in the HIF pathway 
or hypoxic conditions has not been fully revealed as yet. 
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        3 Diabetes  
 
All forms of diabetes are characterized by hyperglycemia, a relative or 
absolute lack of insulin action, pathway-selective insulin resistance, and the 
development of diabetes-specific pathology in the retina, renal glomerulus, and 
peripheral nerve. Diabetes is also associated with accelerated atherosclerotic 
disease affecting arteries that supply the heart, brain, and lower extremities. In 
addition, diabetic cardiomyopathy is a major diabetic complication [53]. 
The majority of publications regarding the mechanisms underlying 
hyperglycemia-induced diabetic vascular damage focus on the 5 major 
mechanisms indicated above. However, the results of clinical studies in which 
only 1 of these  pathways is blocked have been disappointing [54]. This led to 
that all 5 mechanisms are activated by a single upstream event: mitochondrial 
overproduction of the ROS. 
 
1) Increased Polyol Pathway Flux: the polyol pathway is based on a family of 
aldo-keto reductase enzymes that can use as substrates a wide variety of 
carbonyl compounds and reduce these by NADPH to their respective sugar 
alcohols (polyols). It was first thought that glucose is converted to sorbitol by 
the enzyme aldose reductase, with sorbitol then oxidized to fructose by the 
enzyme sorbitol dehydrogenase (SDH), with NAD+ as a cofactor. Several 
mechanisms have been proposed to explain how hyperglycemia-induced 
increases in polyol pathway flux could damage the tissues involved. The most 
cited is an increase in redox stress caused by the consumption of NADPH. 
Because NADPH is a cofactor required to regenerate reduced glutathione 
(GSH), and GSH is an important scavenger of ROS, this could induce or 
exacerbate intracellular oxidative stress [55]. 
2) Increased Intracellular AGE (Advanced Glycation End products) 
Formation: AGEs are formed by the nonenzymatic reaction of glucose and 
other glycating compounds derived from glucose and increased fatty acid 
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oxidation in arterial endothelial cells and most likely heart (eg, dicarbonyls 
such as 3-deoxyglucosone, methylglyoxal, and glyoxal) with proteins [56]. 
Intracellular production of AGE precursors can damage cells by 3 general 
mechanisms. 
Firstly, intracellular proteins modified by AGEs have altered function. 
Secondly, extracellular matrix components modified by AGE precursors 
interact abnormally with other matrix components and with matrix receptors 
(integrins) that are expressed on the surface of cells. Finally, plasma proteins 
modified by AGE precursors bind to AGE receptors on cells such as 
macrophages, vascular endothelial cells, and vascular smooth muscle cells 
[57].  
Clinically, diabetes is associated with poor outcomes following acute vascular 
occlusive events. Diabetic animals have a decreased vascular density 
following hindlimb ischemia and impaired wound healing. Human angiograms 
demonstrate fewer collateral vessels in diabetic patients compared with non 
diabetic controls. Clinically, this contributes to increased rates of lower limb 
amputation, heart failure, and increased mortality after ischemic events. These 
defects result in part from a failure to form adequate compensatory 
vasculogenesis in response to ischemia. 
High glucose induces a decrease in transactivation by the transcription factor 
hypoxia-inducible factor (HIF)-1α, which mediates hypoxia-stimulated 
chemokine and vascular endothelial growth factor (VEGF) production by 
hypoxic tissue, as well as chemokine receptor and endothelial nitric oxide 
synthase (eNOS) expression in endothelial precursor cells in the bone marrow 
[53]. 
3) AGEs can signal through the cell surface receptor called “RAGE,” which is a 
receptor for other non-AGE proinflammatory-related molecules as well. RAGE 
is highly conserved across species and expressed in a wide variety of tissues. 
It is up-regulated at sites of diseases such as atherosclerosis and Alzheimer . 
One of the main consequences of RAGE–ligand interaction is the production 
of intracellular ROS via the activation of an NADPH oxidase system. The ROS 
produced in turn activate the Ras–MAPK pathway, leading to activation of NF-
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κB. Activation of NF-κB results in the transcriptional activation of many gene 
products, one of which is RAGE, as well as many others associated with 
diseases such as atherosclerosis [53]. 
4) Increased Protein Kinase C Activation: PKCs are a family of at least 11 
isoforms that are widely distributed in mammalian tissues. The enzyme 
phosphorylates various target proteins. The activity of the classic isoforms is 
dependent on both Ca2+  ions and phosphatidylserine and is greatly enhanced 
by diacylglycerol (DAG).  Persistent and excessive activation of several PKC 
isoforms operates as a third common pathway mediating tissue injury induced 
by diabetes-induced ROS [53]. Hyperglycemia primarily activates the β and δ 
isoforms of PKC in cultured vascular cells. In the diabetic retina, 
hyperglycemia persistently activates protein kinase C and p38α mitogen-
activated protein kinase (MAPK) to increase the expression of a previously 
unknown target of PKC signaling, SHP-1 (Src homology-2 domain–containing 
phosphatase-1), a protein tyrosine phosphatase. This signaling cascade leads 
to platelet-derived growth factor (PDGF) receptor-β dephosphorylation and a 
reduction in downstream signaling from this receptor, resulting in pericyte 
apoptosis [58]. The same pathway, activated by increased fatty acid oxidation 
in insulin-resistant arterial endothelial cells and heart, may play an equally 
important role in diabetic atherosclerosis and cardiomyopathy. Over-activity of 
PKC has been implicated in the decreased NO production in smooth muscle 
cells, and has been shown to inhibit insulin-stimulated expression of eNOS in 
cultured endothelial cells. Activation of PKC by high glucose also induces 
expression of the permeability enhancing factor VEGF in vascular smooth 
muscle cells [59]. 
5) Increased Hexosamine Pathway Flux: Hyperglycemia and insulin 
resistance–induced excess fatty acid oxidation also appear to contribute to the 
pathogenesis of diabetic complications by increasing the flux of fructose 6-
phophate into the hexosamine pathway. In this pathway, fructose 6-phosphate 
is diverted from glycolysis to provide substrate for the rate-limiting enzyme of 
this pathway, glutamine:fructose 6-phosphate amidotransferase (GFAT). 
GFAT converts fructose 6-phosphate to glucosamine 6-phosphate, which is 
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then converted to UDP-NAcetylglucosamine. Specific O-GlcNAc transferases 
use this for posttranslational modification of specific serine and threonine 
residues on cytoplasmic and nuclear proteins by O-GlcNAc. Inhibition of GFAT 
blocks hyperglycemia-induced increases in the transcription of both TGF-α and 
TGF-β. Although it is not entirely clear how increased flux through the 
hexosamine pathway mediates hyperglycemia-induced increases in the gene 
transcription of key genes such as TGF-α, TGF-β1, and PAI-1, it has been 
shown that hyperglycemia causes a 4-fold increase in O-GlcNAcylation of the 
transcription factor Sp1, which mediates hyperglycemia induced activation of 
the PAI-1 promoter in vascular smooth muscle cells  and of TGF-β1 and PAI-1 
in arterial endothelial cells [53]. 
 
 
ROS production in Diabetes 
 
Oxidative stress is thought to be a major risk factor in the onset and 
progression of diabetes. Many of the common risk factors, such as obesity, 
increased age, and unhealthy eating habits, all contribute to an oxidative 
environment that may alter insulin sensitivity either by increasing insulin 
resistance or impairing glucose tolerance. The mechanisms by which this 
occurs are often multifactorial and quite complex, involving many cell signaling 
pathways. A common result of both types of diabetes is hyperglycemia, which 
in turn contributes to the progression and maintenance of an overall oxidative 
environment. 
Macro- and micro-vascular complications are the leading cause of morbidity 
and mortality in diabetic patients, but the complications are tissue specific and 
result from similar mechanisms, with many being linked to oxidative stress. 
There is a large body of clinical evidence correlating diabetic complications 
with hyperglycemic levels and length of exposure to hyperglycemia. In Fig 10 
have been presented  principal sources of ROS production in diabetes 
mellitus. There are numerous data which demonstrate mitochondria ROS 
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overproduction (first of all superoxide) in diabetes and diabetic complications 
although it is difficult to identify the exact sites of ROS formation [60].  
Disorder of physiological signaling functions of reactive oxygen species (ROS) 
superoxide and hydrogen peroxide and reactive nitrogen species (RNS) nitric 
oxide and peroxynitrite is an important feature of diabetes mellitus type 1 and 
type 2. It is now known that hyperglycemic conditions of cells are associated 
with the enhanced levels of ROS mainly generated by mitochondria and 
NADPH oxidase. It has been established that ROS stimulate many enzymatic 
cascades under normal physiological conditions, but hyperglycemia causes 
ROS overproduction and the deregulation of ROS signaling pathways initiating 
the development of diabetes mellitus.  
High glucose (HG) can initiate the production of superoxide and hydrogen 
peroxide, precursors of reactive free radicals, which are able to stimulate the 
decline of antioxidant systems, directly damage many biomolecules, increase 
lipid peroxidation and develop the insulin resistance in diabetes. For example, 
Graier et al. proposed that HG can induce superoxide formation in aortic 
endothelial cells through metal-mediated oxidation. Du et al. showed that the 
incubation of human endothelial cells (HUVEC) with high glucose led to rapid 
increase in ROS formation, the activation of nuclear factor NFκB, the induction 
of apoptosis and NO synthase uncoupling by a glucose-specific mechanism. 
They also suggested that peroxynitrite can be a mediator of the cytotoxic 
effects of high glucose in endothelial cells [61]. 
Mitochondrial ROS have also been implicated in diabetic complications and 
progression of the underlying diabetic state; however, it is not clear whether 
mitochondria of diabetic origin really generate ROS independently of the 
surrounding diabetic milieu. Herlein et al. showed that the gastrocnemius, 
heart and liver mitochondria of streptozotocin diabetic rats were not irrevocably 
altered to produce excess superoxide either by complex I or complex III. 
Moreover, gastrocnemius and heart mitochondria demonstrated an increase 
and not decrease in respiratory coupling. In addition, mitochondria of insulin-
deficient diabetic rats did show the signs of ROS overproduction [62]. 
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Fig 10. Induction of ROS formation by glucose in diabetes. Glucose enhanced ROS formation 
that induced apoptosis through the nuclear factor NFκB activation and NOS uncoupling in 
human endothelial cells.5 Hyperglycemia increased endothelial superoxide that impaired 
smooth muscle cell Na+-K+-ATPase activity.6  Glucose enhanced the formation of glycated 
proteins and superoxide formation.7  
Mitochondrial superoxide production in diabetes. Glucose stimulated superoxide formation in 
diabetic mitochondria.9-12,14 Glucose decreased or was not changed mitochondrial 
superoxide formations.15,16. (from Igor Afanas’ev, Oxidative Medicine and Cellular Longevity, 
2010) 
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Impairment of HIF-1α regulation in diabetes 
 
Both hyperglycemia and hypoxia are important hallmarks of diabetic 
complications and appear to elicit several deleterious effects, leading to 
complications such as diabetic retinopathy, poor wound healing, neuropathies, 
cardiovascular and renal diseases. A feature that characterizes many of these 
complications is endothelial dysfunction  mainly resulting from impaired 
ischemia-driven neovascularisation. It has consistently been observed that 
diabetic animals have decreased vascular density following hind limb ischemia 
and impaired wound healing [63]. Indeed, it has been extensively shown that 
ischemia induced production of eNOS, SDF-1, CXCR4, VEGF and other 
growth factors is decreased in diabetic tissues and in hyperglycemia [64]. 
In coronary heart disease, mRNA and protein levels of VEGF and its receptors 
VEGFR1 and VEGFR2 in the myocardium were found to be decreased by 40–
70% both  in diabetic rats and in insulin-resistant non-diabetic rats. Moreover, 
a twofold reduction in VEGF and VEGFR2 was observed in ventricles from 
diabetic patients compared with levels in ventricles from non-diabetic donors. 
In addition, decreased levels of VEGF in the renal glomeruli were correlated 
with podocyte cell death, diminished tissue repair and progression of renal 
disease in diabetic patients [65], 
A number of independent reports have suggested that cellular adaptation to 
low oxygen is compromised in the presence of hyperglycemia, culminating in 
increased cell death and tissue dysfunction. For example, blood glucose levels 
showed a linear relationship with fatal outcome in response to an acute 
hypoxic challenge (i.e. acute myocardial infarction). It was further shown that 
AGEs, formed from dicarbonyls such as methylglyoxal, attenuate the 
angiogenic response in vitro, while in diabetic mice, inhibition of the formation 
of AGEs can restore ischemia induced angiogenesis in peripheral limbs [35]. 
Since HIF-1 is the master regulator of the cellular response to hypoxia, it is not 
surprising that HIF-1 deregulation is directly associated with the loss of cellular 
adaptation to low oxygen in diabetes. Indeed, there is a large body of evidence 
supporting this hypothesis and showing that HIF-1α is destabilized at low 
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oxygen levels by high glucose concentrations. It has been shown that  high 
glucose decreases hypoxia-induced stabilization and function of  HIF-1α in 
human dermal fibroblasts and human dermal microvascular endothelial cells in 
culture. This destabilization was not prevented by a prolyl hydroxylase inhibitor 
(ethyl 3,4-dihydroxybenzoate or EDBH), suggesting that other non-canonical 
mechanisms may be involved in the regulation of HIF-1α protein turnover in 
the presence of high glucose. In addition, HIF-1α production was found to be 
impaired during healing of large cutaneous wounds in young db/db mice and 
up-regulation of HIF-1α by gene-based therapy was shown to accelerate 
wound healing and angiogenesis in this model. Moreover, levels of HIF-1α 
were found to be decreased in biopsies from foot ulcers of diabetic patients as 
compared with venous ulcers that share the same hypoxic environment but 
are not exposed to hyperglycemia [66]. 
Downregulation of HIF-1 in response to hyperglycemia also appears to 
account for the decreased arteriogenic response triggered by myocardial 
ischemia in diabetic patients. In rats, myocardial infarct size increases in 
response to hyperglycemia and is associated with reduced production of the 
HIF-1α protein. As mentioned above, endothelial dysfunction in diabetes is 
related to impairment of hypoxia-induced production of eNOS, SDF-1, CXCR4 
and VEGF. This impairment can presumably be ascribed to destabilization of 
HIF-1α, since overexpression of Hif-1α normalizes VEGF levels, improves 
development of myocardial capillary network and inhibits cardiomyocyte 
hypertrophy and cardiac fibrosis following myocardial injury [67]. In addition, 
increased expression or stabilization of HIF-1α is critical to improve wound 
healing [68] and it enhances the vascular response to critical limb ischemia in 
diabetic mice. This mechanism appears to involve an increase in limb 
perfusion and function, an increase in the number of circulating EPCs, vessel 
density and luminal area and a decrease in tissue necrosis [69].  
Important findings include the observation that, compared with non-diabetic 
patients, patients with type 2 diabetes have decreased HIF-1β mRNA levels in 
pancreatic islets, suggesting that changes in the function of HIF-1 can 
contribute to the development of diabetes. A human HIF-1α genetic 
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polymorphism that results in P582S is associated both with type 2 diabetes 
[70] and the absence of coronary collaterals in patients with ischemic heart 
disease. These observations highlight a critical link between diabetes, the HIF-
1 pathway and endothelial dysfunction. 
Although the molecular mechanisms that underlie impairment of HIF-1 in 
diabetes remain poorly understood, some recent studies envision pathways 
whereby diabetes may lead to the downregulation of HIF-1. For example, 
Gurtner and collaborators reported two different mechanisms, both relying on 
the effect of increased availability of methylglyoxal [64, 71] in diabetes. Indeed, 
the authors showed that methylglyoxal modifies HIF-1α in hypoxic mouse 
dermal fibroblasts on two specific residues, arginine 17 and arginine 23, both 
of which belong to the basic helix-loophelix domain that is critical for the 
interaction with HIF-1β and formation of an active heterodimer. These 
modifications consistently reduced HIF-1 heterodimer formation  and Glo1 
(which encodes glyoxalase 1, the rate-limiting enzyme in the detoxification of 
methylglyoxale) overexpression prevented this impairment, emphasising the 
role of methylglyoxal in the loss of the cellular response to hypoxia in diabetes  
[64]. 
In a more recent study, it has been suggested that high glucose decreases the 
interaction between p300 and HIF-1α as a result of increased modification of 
p300 by methylglyoxal. Mutation of arginine 354 of p300 completely prevented 
high-glucose-induced methylglyoxal modification of p300 and restored the 
interaction with HIF-1α. The authors noted that methylglyoxal-induced 
modification of HIF-1α did not impair HIF-1α–p300 binding; however, a 
decrease in VEGF production was still observed, suggesting that impairment 
of associations between both HIF-1α–HIF-1β and HIF-1α–p300 might underlie 
the diabetes-induced defect in HIF-1 transcriptional activity. The authors 
further observed that the iron chelator Deferoxamine (DFO) improves HIF- 1α–
p300 binding and augments HIF-1 activity and VEGF production at high 
glucose levels, by preventing p300 modification by methylglyoxal via a 
mechanism dependent on the decreased production of reactive oxygen 
species [71]. 
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Dimethyloxalylglycine (DMOG), an oxoglutarate analogue known to be a 
potent inhibitor of PHDs, did not show the same effects as DFO, suggesting 
that DFO-induced effects are not likely to be dependent on PHDs and to 
influence HIF-1α protein stability. Alternatively, DFO appears to normalise the 
high glucose-induced defect in HIF-mediated transactivation, by a mechanism 
dependent on the decreased production of reactive oxygen species. The 
physiological significance of this mechanism is indicated by the observation 
that DFO enhances wound healing and neovascularisation in diabetic mice  
[71]. 
In a recent study, Bento and his group proposed a different mechanism for the 
regulation of HIF-1 under high glucose and hypoxic conditions, which also 
relies on methylglyoxal induced modifications. We showed that methylglyoxal 
is capable of inducing modifications on HIF-1α (such as the formation of 
methylglyoxal-derived hydroimidazolone 1, also referred to as MG-H1, 
adducts), leading to the increased association of HIF-1α with the molecular 
chaperones HSP40 and HSP70. These molecular chaperones subsequently 
recruit CHIP, which induces the polyubiquitination of HIF-1α and its 
degradation [72]. This mechanism of degradation appears to be mostly 
dependent on the proteasome, although other proteolytic pathways might also 
be involved in the degradation of methylglyoxal-modified HIF-1α. Canonically, 
CHIP has a key role in protein quality control by inducing  ubiquitination of 
damaged proteins. The ability of CHIP to ubiquitinate HIF-1α under these 
conditions unravels an unanticipated role for CHIP in the loss of the cellular 
response to hypoxia under high glucose conditions such as diabetes. 
Interestingly, CHIP was also found to induce HIF-1α proteasomal degradation 
by a mechanism dependent on HSP70 in response to prolonged hypoxia [73]. 
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and Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
1 Mitochondrial bioenergetics at low 
oxygen levels 
 
 
Aim 
 
Mitochondria are small organules with a central role in energy supply in cells, 
ROS production and apoptosis. Mitochondria have been implicated in several 
human disease and mitochondrial dysfunctions in hypoxia have been related 
with disorders like Type II Diabetes, Alzheimer Disease, inflammation, cancer 
and ischaemia/reperfusion in heart. 
When oxygen availability becomes limiting in cells, mitochondrial functions are 
modulated to allow biologic adaptation. Different mitochondrial responses 
reported in  literature depend on the degree of hypoxia, the duration of 
exposure, and the type of cells. The fine regulation of mitochondrial function 
has proved to be an essential metabolic adaptation to fluctuations in oxygen 
availability.  
Cells exposed to a reduced oxygen concentration readily respond by adaptive 
mechanisms to maintain the physiological ATP/ADP ratio, essential for their 
functions and survival. In the beginning, the AMP-activated protein kinase 
(AMPK) pathway is activated [74], but the responsiveness to prolonged 
hypoxia requires the stimulation of hypoxia-inducible factors (HIFs). 
HIFs are master transcription factors regulated in an O2-dependent manner by 
a family of prolyl hydroxylases (PHDs), which use O2 as a substrate to 
hydroxylate HIF-a subunits in conditions of normoxia [41]. These hydroxylated 
substrates are then ubiquitinated after recognition by VHL, and they are 
degraded by the proteasome. By contrast, PHD activity is inhibited in hypoxic 
conditions, and accordingly, HIF-α subunits accumulate, heterodimerize with 
HIF-β, and activate the expression of HIF-dependent target genes [75-76]. 
80-90% of oxygen in cells is consumed by mitochondrial respiration and in 
hypoxic conditions, the enzymes involved in oxidative phosphorylation 
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(OXPHOS), are supposed  to be down-regulated. It has been shown  that the 
mitochondrial respiration rate of cells exposed to a hypoxic  environment was  
decreased but the molecular mechanism is still unclear. More recently, it has 
been  reported that activation of HIF-1α induces pyruvate dehydrogenase 
kinase, which inhibits pyruvate dehydrogenase, suggesting that respiration is 
in fact decreased by substrate limitation [77]. Other reports have suggested 
that oxygen utilization is shifted in cells exposed to low O
2 
levels due to nitric 
oxide (NO) inhibition of cytochrome c oxidase [78]. 
In this thesis we report a study of the mitochondrial bioenergetics of primary 
cells exposed to a prolonged hypoxic period . To shine light on this issue we 
examined the bioenergetics of fibroblast mitochondria cultured in hypoxic 
atmospheres (1% O
2
) for 72 hours. Here we report on the mitochondrial 
organization in cells and on their contribution to the cellular energy state.  
 
 
Growth of primary Human Dermal Fibroblasts at different 
oxygen tension 
 
In this experiment we compared the cellular growth in fibroblasts cultured in 
5mM glucose and exposed at different oxygen tension ( from 21% to 0.5%). 
As shown in figure 1 (left), the difference in  oxygen levels does not 
significantly affect the  growth, it means that  the cell growth is not dependent 
on the oxygen tension. We hypothesized that this was due to the ability, of the 
cells cultured in different conditions, to maintain the same ATP availability. We 
measured the intracellular ATP content (figure 11 right) and we found a 
decrease of maximum 20% at 0.5% O2. During hypoxia,  ATP content does not 
change significantly since  glycolysis becomes the main source of ATP. 
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figure 1. (left) Growth of  fibroblasts cultured in 5mM glucose for 72 hours at different oxygen 
concentrations. (right) Intracellular ATP content at different experimental conditions.  
Data are shown as average ± SD of three in-dependent experiments. 
 
 
 
Oxidative phosphorylation and mitochondrial mass in hypoxia 
 
Mitochondrial function has been evaluated in fibroblasts cultured in 5mM 
glucose at 21% O2  and 1% O2 for 72 hours . ATP synthesis rate has been 
considered as parameter for testing the effect of hypoxia on OXPHOS, it 
means on cellular energetic capability. 
We measured Complex I-driven ATP synthesis in digitonin-permeabilized cells 
and in the presence of malonate, an inhibitor of succinate dehydrogenase 
complex. After inducing the in vitro ATP synthesis for 3 minutes, ATP 
extracted from samples was quantified with a chemiluminescent method based 
on luciferin-luciferase reaction using a known amount of ATP as standard. 
As shown in figure 2 (left panel), cells exposed to 1% oxygen are 
characterized by a reduced capability (60%) to synthesize ATP in presence of 
Complex I substrates. Since   when we measured the citrate synthase activity 
(figure 2-right panel),we found a decrease in mitochondrial mass, we 
explained the reduction in ATP synthesis is due to the decrease of number of 
mitochondria. In figure 3, the ATP synthesis rate values have been reported 
after normalization to citrate synthase activity of each analyzed sample. We 
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can conclude that most of the reduction in OXPHOS capability is due to the 
reduction of mitochondrial mass. 
 
 
 
 
 
 
 
 
 
 
 
figure 12. Complex I-driven ATP synthesis rate (left panel), ATP synthesis rate in presence 
of NADH-dependent substrates. Citrate Synthase activity (right panel). 
 
 
 
 
 
 
 
 
 
 
 
 
figure 3. ATP synthesis rate, ATP synthesis rate in presence of NADH-dependent substrates 
in fibroblasts cultured at 21% and 1% O2. Values were normalized by citrate synthase activity 
considered as index of mitochondrial mass 
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Peroxides in Fibroblasts grown in Hypoxia  
 
We compared the peroxide levels in fibroblasts grown for 72 h either  at 21% 
and 1% O
2 
tension . 21% O
2 
induced the highest DCF fluorescence, 
corresponding to the highest level of peroxides; even though, prolonged 
hypoxia resulted in reduced peroxide levels (Figure 4). However, the  peroxide 
levels decreased in hypoxia, suggesting that the reduction of mitochondrial 
mass has a main role in decreasing ROS producton in hypoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 4. ROS production in intact fibroblasts grown for 72 h in different experimental 
conditions. Reactive species were evaluated by measuring DCF fluorescence in cells 
cultured under normoxic (21% O2) or hypoxic (1% O2) conditions. 
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OXPHOS complexes  in hypoxia exposed-fibroblasts 
 
After  the normalization of the OXPHOS rate versus the mitochondrial mass 
we wanted  to estimate the level of the OXPHOS complexes to clarify how 
hypoxia affects the OXPHOS rate.  Figure 5 shows a significant decrease of 
porin, the protein taken as an index of the mitochondrial mass, and a decrease  
of the OXPHOS complexes I, III, and IV levels in fibroblasts exposed to  
hypoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Immunodetection of OXPHOS complexes after SDS-PAGE separation  
Electrophoretic separation of cell lysates obtained from fibroblasts grown for 72 h in 5 
mM Glucose (i); images have been quantified by QuantityOne Software and hypoxia was 
compared versus normoxia (ii); data were normalized on porin control, taken as internal 
standard (iii). 
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Discussion 
 
Mammalian cells are able to sense decreased oxygen availability and activate 
adaptational responses including transcriptional activation of several hypoxia-
inducible genes: erythropoietin, vascular endothelial growth factor, glycolytic 
enzymes, and glucose transporters. This allows increased O2 delivery through 
enhanced erythropoiesis, angiogenesis and metabolic adaptations that 
facilitate glycolytic ATP production. Hypoxia-inducible factor 1 (HIF-1) is a 
heterodimeric transcription factor that regulates transcriptional activation of 
several genes responsive to the lack of oxygen, including erythropoietin, 
vascular endothelial growth factor, glycolytic enzymes, and glucose 
transporters. 
The mechanisms of sensing low oxygen and transducing this signal to activate 
HIF-1 are not well understood. A role for a putative oxygen sensor molecule 
has been suggested. Another model proposes that the process of sensing 
decreased oxygen concentration involves NADPH oxidase activity.  A 
decrease in available oxygen would result in decreased reactive oxygen 
species formation by NADPH oxidase, and this in turn would activate 
pathway(s) leading to HIF-1 induction [79]. Recently, a different model based 
on the role of the mitochondrial electron transport chain in hypoxia sensing 
was suggested . Inhibition of complex I and complex III of mitochondrial 
respiratory chain blocked HIF-1 DNA binding activity and expression of HIF-1 
target genes in Hep3B cells under hypoxic conditions. In addition to hypoxia, 
several growth factors can activate HIF-1 and its target genes via different 
signaling pathways [80]. 
In 1998 Chandel [81] suggested that mitochondria may play a wider role in the 
functional responses of eukaryotic cells to changes in O2 concentration. 
On the base of the studies reported, we evaluated how mitochondria are 
involved in the adaption to hypoxia. 
The first evidence provided in this thesis is that long term  hypoxia does not 
induce death of primary human fibroblasts. Previous studies showed that when 
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cells are exposed to hypoxia, glycolysis is stimulated  and  it can compensate 
the reduction of ATP production by oxidative phosphorilation [82]. 
Our data show that, despite ATP synthesis rate is reduced when oxygen 
availability decreases,  the exposure of fibroblast to any oxygen level (4%, 
2%,1%,0.5%)  do not significantly affect the total ATP content, which is quite 
the same level of normoxia. These data might confirm  the hypothesis reported 
above, that cells respond  to lowered oxygen tension by increasing the amount 
of glycolytic enzymes and glucose transporters via the well-characterized 
hypoxia-inducible factor-1 (HIF). However, HIF is also responsible for  the 
overexpression of lactate dehydrogenase (LDH), wich converts pyruvate in 
lactate with concomitant production of NAD+, which is used in glycolysis. HIF 
also upregulates pyruvate dehydrogenase kinase 1 (PDK1), that inhibits the 
pyruvate dehydrogenase (PDH) decreasing TCA cycle and consequently 
oxidative phosphorylation in mitochondria. 
The decrease of mitochondrial mass at 1% of oxygen explains  the reduction 
of the ATP synthesis rate, that might be due, as reported  by Thomas R.L. et 
al., 2011 [83], to the activation of mitochondrial autophagy, a mechanism  
involving the catabolic degradation of macromolecules and organelles in order 
to regenerate metabolites and promotes survival by reducing radical oxygen 
species (ROS) and DNA damage under hypoxic conditions.  
The normalization of the ATP synthesis rate on citrate synthase activity 
highlighted that the decrease in ATP synthesis rate at 1% oxygen is not only 
due to a reduction in the number of mitochondria but it can occur through a 
different mechanism, linked to a dysfunction of mitochondrial complexes. From 
the quantitative analysis of the OXPHOS complexes by western blot, we can 
conclude that cells exposed to 1% O2 are characterized by a reduction  in the 
quantity of each complex, especially complex I, III, IV. 
The role of oxidative stress in cells and tissues exposed to hypoxia is 
controversial, and the direct measurement of the effect of hypoxia on oxidative 
stress in human tissues has not been deeply understood under conditions of 
prolonged exposition to moderate hypoxia.  Several studies support the 
hypothesis that hypoxia reduces ROS production in mitochondria since it 
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decreases mitochondrial respiration, others suggested  that hypoxia increases 
ROS production because of its role in stabilize HIF. 
In our hands, our data show that ROS level decrease in hypoxia as results of 
the reduction of oxidative phosphorylation activity in mitochondria and of 
mitochondrial mass.  
 
Our results indicate that prolonged hypoxia cause a significant reduction of 
mitochondrial mass and of the quantity of the oxidative phosphorylation 
complexes. Thus, hypoxia is also responsible to damage mitochondrial 
complexes as shown after normalization versus citrate synthase activity. 
This study demonstrated that to promote adaption and their survival, cells 
need to change their metabolism when are exposed to a crisis status, like 
hypoxia. 
It is important to understand how cells try to adapt to hypoxia and which 
pathways are involved and also the role of mitochondria in it, the  biochemical 
mechanisms in order to define possible therapeutic targets. 
A better understanding of the mechanism at the base of the adaption to 
hypoxia is useful to help in studying a lot of important pathologies in which the 
lack of oxygen  is a common issue, such as heart ischemia, cancer, and 
diabetic complications. 
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2 Modulation of mitochondrial structure and 
function  in hypoxia and hyperglycemia 
 
Aim 
 
Chronic complications of diabetes (retinopathy, nephropathy, neuropathy, and 
diabetes-accelerated arteriosclerosis) represent a major medical and 
economical concern. 
All forms of diabetes are characterized by chronic hyperglycemia and the 
development of diabetes-specific microvascular pathology in the retina, renal 
glomerulus and peripheral nerve. As a consequence of its microvascular 
pathology, diabetes is a leading cause of blindness, end stage renal disease 
and a variety of debilitation neuropathies. Diabetes is also associated with 
accelerated atherosclerotic macrovascular disease affecting arteries that 
supply the heart, brain and lower extremities. As a result, patients with 
diabetes have a much higher risk of myocardial infarction, stroke and limb 
amputation [84]. 
The worldwide incidence of diabetes is set to rise dramatically from the 
present incidence of 150 million to an estimated 300 million in 2025 and 
assorted complications affecting the vascular system, kidney, and peripheral 
nerves are common and extremely costly in terms of longevity and quality of 
life [68]. 
The vast majority of publications about the mechanisms underlying 
hyperglycemia-induced diabetic vascular damage, focus on five major 
mechanisms: increased flux of glucose and other sugars through the polyol 
pathway, increased intracellular  formation of advanced glycation end-products 
(AGEs), increased expression of the receptor for advanced glycation end-
products and its activating ligands, activation of protein kinase C (PKC) 
isoforms, and overactivity of the hexosamine pathway. In 2000 was 
hypothesized that all five mechanisms are activated by a single upstream 
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event: mitochondrial overproduction of the reactive oxygen species (ROS)  
[53]. 
It is well established that hyperglycemia elicits an increase in reactive oxygen 
species (ROS) production, due to increased input of reducing equivalents into 
the mitochondrial electron transport chain [85]. The pathogenesis of chronic 
ulcers in diabetes is still unclear. A critical stimulus for normal wound healing is 
relative hypoxia and an impaired reaction to hypoxia could contribute to 
impaired wound healing. Under hypoxic conditions, HIF-1α is stabilized against 
degradation and transactivates and up-regulates a series of genes that enable 
cells to adapt to reduced oxygen availability. 
HIF-1α plays a pivotal role in wound healing, and its expression in the 
multistage process of normal wound healing has been well characterized, it is 
necessary for cell motility, expression of angiogenic  growth factor and 
recruitment of endothelial progenitor cells [86]. 
Catrina et al., [66, 87] have shown that hyperglycemia impairs HIF-1α stability 
and function. 
ROS and HIF are strictly related, and several mechanisms are activated by 
HIF to contribute to the reduction of the ROS production in hypoxia. HIF can 
activate autophagy (mitophagy) by inducing BNIP3 and by this mechanism 
reduces the amount of ROS-producing organelles [47]. 
Physiological hypoxia induces a COX4-1 to COX4-2 subunit switch, an effect 
mediated by HIF-1 that is thought to optimize the efficiency of respiration 
during conditions of reduced oxygen availability [46]. 
Tello et al. [48], proved that mitochondrial Complex I activity is controlled by 
NDUFA4L2 during hypoxia and its induction during hypoxia helps keep 
intracellular ROS production in check, consistent with the fact that NDUFA4L2 
limits Complex I activity and prevents increases in membrane potential. 
Another effect of HIF on ROS production and mitochondria is the activation of 
pyruvate dehydrogenase (PDH) kinase 1 (PDK1), which phosphorylates and 
inactivates in its turn the catalytic subunit of PDH, the enzyme that converts 
pyruvate to acetyl coenzyme A.  In this way it prevents the entry of pyruvate 
into tricarboxylic acid (TCA) cycle and by this decreases the flux through 
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electron transport counteracting the reduced efficiency of electron transport in 
hypoxia that would produce excessive ROS. 
Catrina et al. [66], demonstrated that hyperglycemia impairs HIF-1α stability 
and function and has been suggested  that by this it contributes to the 
development of chronic complications of diabetes (wound healing, coronary 
heart disease, nephropathy, etc.).  
The results reported in this dissertation have been obtained at Rolf Luft 
Research Center for Diabetes, Karolinska Institutet in Stockholm and derive 
from a project focused on the study of the modulation of mitochondria structure 
and function induced by hypoxia and hyperglycemia and on prove the role of 
HIF-1α destabilization in the increase of ROS production by mitochondria. Our 
hypothesis was that HIF-1α destabilization induced by hyperglycemia is 
responsible of the increase of ROS production during hypoxia. 
We therefore studied the effect of hyperglycemia and hypoxia on human 
dermal ﬁbroblasts (HDFs) and human dermal microvascular endothelial cells 
(HDMECs) that were grown in high glucose, low glucose concentrations and  
mannitol as control for the osmotic challenge. Cells were cultured in normoxia 
(21% O2) and hypoxia (1% O2). 
 
 
High glucose and hypoxia increases ROS production in HDFs 
and HDMEC 
 
In order to investigate ROS production induced by hyperglycemia and 
or/hypoxia, HDFs and HDMEC cells were cultured in 5 mM glucose, 30 mM 
glucose and 30 mM mannitol and were incubated either in hypoxia chamber 
(1% O2) and normoxia (21% O2)  for 18 hours. After the incubation cells were 
analyzed by flow cytometry. We used the carboxy-methyl-H2DCFDA probe 
that loses the acetate groups when cleaved by esterases after cell entry, 
leading to intracellular trapping of the non-ﬂuorescent 2’, 7’dichloroﬂuorescein. 
It is a widely used probe for its ability to detect a wide spectra of ROS that 
induce its subsequent oxidation, to the highly ﬂuorescent product 
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dichloroﬂuorescein. For evaluating mitochondrial ROS, we use the MItosox 
Red probe, that permeates live cells where it selectively targets mitochondria. 
It is rapidly oxidized by superoxide but not by other reactive oxygen species 
(ROS) and reactive nitrogen species (RNS). 
Interestingly, in contrast with the studies presented, here we show that in  
normoxia, both in HDFs and HDMEC high glucose does not induce ROS 
production as shown in figure 16. CM-DCFDA and Mitosox Red fluorescences 
did not present any difference between high glucose and low glucose 
exposed-cells. Indeed, the combination of hypoxia and hyperglycemia for 18 
hours induced an increase in ROS production, which has been pointed out by 
the high fluorescence of both DCFDA and Mitosox Red, either in HDFs or 
HDMEC. 
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Figure 16. ROS detection in HDFs (upper panel) and HDMEC (lower panel) cells. The 
CM-H2DCFDA passively diffuses into cells, where its acetate groups are cleaved by 
intracellular. Subsequent oxidation yields a fluorescent adduct that is trapped inside the cell.  
The Mitosox Red targets superoxide in mitochondria.  
 
 
High glucose and hypoxia trigger apoptosis 
 
Our observation that the combination of hypoxia and hyperglycemia increased 
ROS production, prompted us to investigate the effect of ROS on apoptosis. 
We evaluated apoptosis by staining with Annexin V-FITC after a prolonged 
exposure of 5 days to hypoxia and hyperglycemia. As shown in figure 17, 
apoptotic cells were not detected neither in normoxia (either in low glucose or 
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high glucose,) nor in hypoxia and 5.5 mM glucose.  The combination of 
hypoxia and hyperglycemia induces apoptosis, as shown by the percentage of 
cells Annexin V-FITC positive in Q4 quadrant.  There is also an increase of 
cells in late apoptosis, as  shown by the increase of Annexin V and PI staining 
in the Q2 quadrant. We hypothesized that the ROS overproduction enhanced 
by high glucose and hypoxia, accumulates damages in the cells and triggers 
apoptosis, which is detectable after a prolonged exposure to low oxygen levels 
and high glucose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Flow cytometry analysis of apoptosis in HDMEC cells exposed to 
hyperglycemia and hypoxia and hyperglycemia. Representative of two separate 
experiments. Q1 shows necrotic cells PI positive; Q2, Annexin V and PI positive; Q3, live cells 
Annexin V and PI negative; Q4, apoptotic cells Annexin V positive.  
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Mitochondrial mass and mtDNA content in hyperglycemia in 
normoxia and hypoxia 
 
In order to investigate the effect of high glucose on mitochondrial mass, we 
evaluated the mitochondrial content by measuring the activity of citrate 
synthase enzyme in HDFs and HDMEC after treatment with low glucose, high 
glucose and mannitol in hypoxia and normoxia for 3 and 5 days. The enzyme 
activity in normal growth condition (5.5 mM glucose in normoxia) was also 
evaluated and correspond to the activity at time 0. 
In HDFs (figure 18a) in hypoxia, citrate synthase activity is reduced of  about 
35% (P<0.05) after 3 days and the reduction is of 45% (P<0.05) after 5 days, 
with respect to the control cells cultured in 5.5 mM glucose. 
In HDMEC (figure 18b) in hypoxia, citrate synthase activity is reduced of  
about 27% (P<0.05) after 3 days and the reduction is of 43% (P<0.05) after 5 
days. Each condition has been compared to the control cells, cultured in 5.5 
mM glucose. 
In both cell lines, the decrease in mitochondrial mass in hypoxia is 
independent of glucose concentration and mannitol. No significant  differences 
in mitochondrial content have been observed in different experimental 
conditions in normoxia. 
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figure 18. Citrate Synthase activity in a) HDFs and b) HDMEC after 3 and 5 days in different 
experimental conditions. 
 
 
 
It has been reported that under pathological conditions, mitochondrial 
abundance as well as the copy number of mtDNA in cells changes in response 
to increases in oxidative status. Since oxidative stress is elevated in the 
hyperglycemic state, we evaluated  and compared the effect of only 
hyperglycemia in normoxia and combined hyperglycemia and hypoxia on 
mtDNA copy number. 
In figure 19 and 20 the mtDNA content is shown in HDFs and HDMEC, 
respectively, after 5 days of exposure to hyperglycemia and both 
hyperglycemia and hypoxia. mtDNA copy number were evaluated by qPCR, 
measuring the ratio between mitochondrial gene cyt b and 16s rRNA and 
nuclear gene GAPDH. Despite hypoxia and/or hyperglycemia increase the 
oxidative stress, the analysis of both mitochondrial genes shows differences in 
mtDNA copy number only between normoxia and hypoxia, independently of 
glucose concentrations, suggesting that the reduction of mtDNA copy number 
is related to the decrease of the number of mitochondria in hypoxia. 
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figure 19 Mitochondrial DNA copy number in HDFs. mtDNA copy number in fibrobasts was 
evaluated after the exposure to hyperglycemia (normoxia No and hypoxia Hy) and 
hyperglycemia plus hypoxia for 5 days. a) shows the ratio between mitochondrial cyt b and 
nuclear GAPDH b) shows the ratio between mitochondrial 16s rRNA and GAPDH. (P value 
<0.05, test di Dunnett vs 5mM glu in normoxia) 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 20 Mitochondrial DNA copy number in HDMEC. mtDNA copy number in endothelial 
cells was evaluated after the exposure to hyperglycemia (normoxia No and hypoxia Hy) and 
hyperglycemia plus hypoxia for 5 days. a) shows the ratio between mitochondrial cyt b and 
nuclear GAPDH b) shows the ratio between mitochondrial 16s rRNA and GAPDH. (P value 
<0.05, test di Dunnett vs 5mM glu in normoxia) 
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Discussion 
 
Increasing evidence of experimental and clinical studies suggest that ROS 
play an important role in the pathogenesis of diabetes. Thus, ROS and in 
particular the overproduction of reactive oxygen species by the mitochondrial 
electron-transport chain, have been implicated in diabetic complications. In 
cells with high glucose inside, there is more glucose being oxidized in the TCA 
cycle, which in effect pushes more electron donors (NADH and FADH2) into 
the electron transport chain. As a result of this, the voltage gradient across the 
mitochondrial membrane increases until a critical threshold is reached. At this 
point, electron transfer inside complex III is blocked, causing the electrons to 
back up to coenzyme Q, which donates the electrons one at a time to 
molecular oxygen, thereby generating superoxide. 
Several studies showed that  hyperglycemia induces mitochondrial ROS 
production in rat mesengial cells [88]. Superoxide production was found 
increased also in leucocytes from patients with diabetes and retinopathy  [89], 
in renal proximal tubular cells [90] and in rat isolated islets [91] and in bovine 
aortic endothelial cells [85]. 
Hypoxia directly or through induction of ROS have been suggested to have an 
important role in the development of diabetic complication. The adaptative 
responses of the cells to hypoxia are mediated by HIF-1α and in 2008 Botusan 
IR [68], demonstrated that several HIF-regulated genes essential for different 
mechanisms activated in wound healing (i.e., migration, recruitment of CAG, 
and angiogenesis) were repressed in diabetic wounds. 
Results presented in this dissertation show that, contrary to what have been 
reported, hyperglycemia does not induce ROS overproduction neither in HDFs 
nor in HDMEC cells cultured in high glucose for 18 hours, in normoxia . This 
might be explained by an adaptation of cells to hyperglycemia or a time-
dependent effect of high glucose in generate reactive oxygen species, which 
might occur after several days when cells are cultured in normoxia. Indeed, the 
combination of both hypoxia and hyperglycemia increase ROS production 
either in HDFs or HDMEC. Based on a previous study where Kim et al. [42], 
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highlighted that  hypoxia induced pyruvate dehydrogenase kinase 1 (PDK1) is 
critical for the attenuation of mitochondrial ROS production and adaptation to 
hypoxia and  since hyperglycemia destabilizes HIF-1α [66], we hypothesized 
that HIF-1α  destabilization increases the flux to oxidative phosphorylation 
through the inhibition of hypoxia-induced PDK1.  
ROS measurement with DCFDA demonstrated that hypoxia and 
hyperglycemia cause ROS overproduction and  Mitosox Red, a specific probe 
for mitochondrial reactive oxygen species, showed that the same treatment 
induces ROS overproduction from mitochondria. 
It is well established that increased ROS production trigger apoptosis. 
Preliminary results on HDMEC, demonstrated that cells undergo apoptosis 
only after a prolonged (5 days) exposure to hypoxia and hyperglycemia, 
indicating that apoptosis in complications of diabetes might be a time-
dependent process and that can be exacerbated when cells are exposed to 
hypoxia and high glucose for a longer period. 
We also evaluated whether the prolonged exposure to hypoxia and 
hyperglycemia could modulate the mtDNA content and despite has been 
reported that hyperglycemia and increased ROS production can change it, we 
did not find any significant difference in normorxia and apparently, the 
reduction we found in hypoxia and high glucose reflects the decrease of 
mitochondrial mass as consequence of the lack of oxygen, as confirmed also 
by the lower citrate synthase activity in hypoxia. Since HIF-1α is induces 
BNIP3, a gene involved in autophagy of mitochondria, we expected to find a 
difference in mitochondrial content in cells exposed to hypoxia and high 
glucose and perhaps an increase, but our data showed that the mitochondrial 
content assayed by citrate synthase activity is not affected. Several studies 
reported that autophagy is also induced by Akt , JNK and FOXO transcription 
factor [92] or by mitochondrial ROS [93]. We hypothesized that , in cells 
cultured in hypoxia and hyperglycemia  a balance between the loss of 
activation of autophagy by HIF-1α and the activation of the autophagy by ROS 
and FOXO transcription factor might establish. This also could be a pathogenic 
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mechanism that allows the accumulation of defective mitochondria and could 
be important for diabetes complications. 
In conclusion, we show here that the exposure of HDFs and HDMEC cells to 
high glucose for 18 hours does not induce any change in ROS production, 
indeed the combination of low oxygen tension and high glucose induces ROS 
overproduction from mitochondria. We speculated that the increased ROS 
levels are dependent on HIF-1α destabilization and on the loss of the 
activation of PDK1 transcription, that is critical for the attenuation of ROS 
production and adaptation to hypoxia. Our data also showed that high glucose 
alone does not affect mtDNA content and mitochondrial mass and that in 
hypoxia and high glucose the decrease of both those parameters do not show 
significant differences with respect to low glucose in hypoxia. Further 
investigations in vitro will carried on a HIF-1α knocked out cell line to confirm 
the dependence of ROS overproduction in hypoxia and high glucose on HIF-
1α destabilization, and afterwards we want to evaluate whether by 
reintroducing HIF-1α expression, it can rescue ROS overproduction. It might 
contribute to understand the pathogenic mechanisms involved in complications 
of diabetes to find new therapeutic targets. 
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3 MODULATION OF ATPase INHIBIYTORY FACTOR (IF1)      
EXPRESSION 
 
Aim 
 
Central to mitochondrial function is an electrochemical proton gradient across 
the mitochondrial inner membrane, that is established by the proton pumping 
activity of the respiratory chain. Impaired mitochondrial function, resulting from 
a variety of different mechanisms, will usually cause a decrease in Δψm as a 
common endpoint.  
The ability of the F1F0-ATP synthase to reverse and act as an ATPase during 
conditions of reduced membrane potential has been appreciated for many 
years.  ATP consumption by the F1Fo -ATPase could represent an important 
pathogenic mechanism in diseases in which mitochondrial respiration is 
compromised. 
These diseases include the lack of oxygen or substrate (as in a stroke or heart 
attack), but also include many diseases in which more subtle defects in 
mitochondria are implicated, including  Alzheimer’s and motor neuron diseases 
and a large number of rare but debilitating diseases that involve genetic 
defects affecting mitochondrial proteins 
The mammalian mitochondrial ATP synthase, consists of 15 different subunits, 
but a 16th subunit is also present, the IF1 inhibitor, a protein which binds at the 
α/β catalytic sites and inhibits ATP hydrolysis. The binding of IF1 to F1 is pH 
dependent being optimal at pH around neutrality [23]. 
When the aerobic proton motive force declines, like in ischemia or respiratory 
substrate deﬁciency, decrease of the matrix pH promotes binding of IF1 to F1, 
with prevention of ATP hydrolysis. 
In conditions of normal generation of the respiratory electrochemical proton 
gradient, resulting  in pH increase in the matrix space, IF1 dissociates from the 
catalytic sites and ATP synthesis takes place normally. 
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The expression of IF1 in human tissues and its participation in the 
development of human pathology are unknown. 
Recently, Campanella et al. [21], found that IF1 is important in regulating the 
mitochondrial fraction. When IF1 was overexpressed the fraction of the cell 
volume occupied by mitochondria was signiﬁcantly increased compared to 
controls with basal IF1 expression levels. Conversely, suppression of IF1 
promoted the opposite result with a decrease in mitochondrial fraction. Thus, 
overexpression of IF1 also has a role in remodeling mitochondrial cristae and  
might have a role as “coupling factor” increasing the efficiency of oxidative 
phosphorylation. 
On the opposite, Sanchez-Cenizo L. et al. [94], demonstrated that IF1 plays a 
role in limiting oxidative phosphorylation  and thus in promoting glycolysis. 
Taken together these results, the aim of this study was to characterize the 
bioenergetics of cell lines  with different expression levels of IF1, modulated by 
silencing and overexpression, in particular  when cells are grown in hypoxia, a 
condition that can mimic different pathologies, such as cancer or heart 
disease. 
 
 
Plasmid construct 
IF1 cDNA was transferred from the original pCMV6-XL4 plasmid, which allows 
transient transfection in mammalian cells, into the pCDNA3 plasmid, that 
allows to perform stable transfection and select stable cell clones over-
expressing IF1 by the selection with the antibiotic G418. In figure 21 the 
plasmids used for cloning are shown, both of them contain a polylinker region, 
where enzyme restriction sites are present,  SV40 ori  that allows for 
replication in mammalian cells and f1 Ori, the philamentous phage origin of 
replication, which allows for the recovery of single-stranded plasmids. 
Selection of the plasmid in E.coli is conferred by the ampicillin resistance 
gene. Only pCDNA3 has the gene for the resistance to Neomycin/G418 used 
for selecting eucariotic cell clones. To cloning IF1 cDNA in pcDNA3 plasmid , a 
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570 bp IF1 fragment was digested with NotI restriction enzyme from pCMV6-
XL4-IF1 plasmid,  and inserted in-frame into the pCDNA3  plasmid digested 
and linearized with the same enzyme NotI.  
 
 
 
 
 
Figure 21. Representation of the plasmidic vector used for cloning.  Red arrows   show the 
restriction sites of Not I  enzyme into the polylinker region.        
 
After ligation reaction by T4 DNA Ligase, which join two strands of DNA 
between the 5’-phosphate and the 3’-hydroxyl groups of adjacent nucleotides 
in either sticky- or blunt-end configuration, the insertion and the correct 
orientation of IF1 cDNA have been checked by PCR. Fig 22a is a schematic 
representation of  the primers binding sites and the 375 bp amplification 
product obtained by amplification. Figure  22b shows the amplification 
products obtained by PCR analysis with the same primers on 24 bacterial 
colonies.  
The black arrows indicate  the 375 bp fragment obtained by amplification 
in four bacterial colonies. 
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figure 22. a) The figure shows the site where the primers bind. The forward 1 binds to the T7 
promoter region and the reverse 4 binds to the internal region of IF1 gene sequence. b) 1,2% 
agarose (EtBr  500 µg/ml) gel used for the screening of IF1 insertion into 24 bacterial colonies.  
 
To verify IF1 insert into the four plasmid was not mutated, analysis by 
sequencing was carried out. The four plasmids have been sequenced using 
the forward primer that binds to the T7 promoter on the filament 5’-3’ and the 
reverse primer that binds to the BGH promoter on the filament 3’-5’. Figure 23 
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shows the representative alignement of the sequence of one bacterial plasmid, 
analyzed by sequencing. The perfect alignement between  IF1 sequences 
analyzed by sequencing and the registered IF1 sequence shows that IF1 gene 
have not been affected by any point mutation during the cloning process. After 
cell transfection, several stable cell clone have been selected by the antibiotic 
G418 and IF1 expression has been analyzed by Western Blot. Figure 24 
shows  IF1 expression  in one pcDNA3-IF1 transfected cell clone compared 
with the control line of 143B transfected with empty pcDNA3. The 
quantification analysis indicates that IF1 expression is 2,5 times more in 
pcDNA3-IF1 than in pcDNA3 scramble; the overexpression was quantified 
(data not shown) and has been normalized versus  the ATP synthase D 
subunit content. 
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figure 24 Western Blot analysis of IF1 expression in 143B cells transfected with pcDNA3 
empty (left) and pcDNA3-IF1 (right) 
 
 
 
 
Effect of IF1 over-expression on ATP hydrolysis and 
membrane potential 
 
The effect of IF1 over-expression has been investigating measuring ATP 
hydrolysis activity in mitochondria isolated from  the parental 143B cell line 
transfected with the empty vector and from the stable cell line over-expressing 
IF1 gene. Since IF1 binds ATP synthase when pH in the matrix drops to about 
6.7, isolated mitochondria have been resuspended in Hepes-buffer with two 
different pH, one at 6.7 to promote IF1 binding to ATP synthase and the other 
at 7.4 in order to find the best  experimental conditions for the assay . In figure 
25 the ATPase hydrolysis activity is shown in two different pH conditions and it 
is expressed as nmol per mg of cellular protein per minute (nmol/min/mg). ATP 
hydrolysis activity in 143B control cells  is reduced of 45% when IF1 binding to 
ATP synthase is stimulated by the pH; the reduction of the activity at pH 6.7 in 
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the clone over-expressing IF1 is greater  (-57%) with respect to the condition 
at pH 7.4. Moreover, in the stable clone even when the pH does not allow the 
binding of IF1 to ATP synthase, we observed a modest reduction of ATP 
hydrolysis 
 (-25%) as compared with parental143B cell line at pH 7.4. Our results show 
that  the cells overexpressing IF1 have a reduced ATP hydrolysis activity, as 
consequence of the increased expression levels of IF1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 25  ATP hydrolysis in 143 B cells transfected with scramble pcDNA3 (left) and pcDNA3-
IF1 (right). (* P<0.05, statistical analysis was performed with Student t test) 
 
We also evaluated the effect of IF1 overexpression on mitochondrial 
membrane potential. We measured the membrane potential by the fluorescent 
probe TetraMethylRhodamine Methyl estere (TMRM), a cell-permeant, 
cationic, red-orange fluorescent dye that is readily sequestered by active 
mitochondria. Fluorescent images in figure 26 show the membrane potential in 
normal growth conditions, that is comparable in both cell lines. When 
Antimycin A, Complex III inhibitor was added, we observed a decrease of 
TMRM fluorescence, as consequence of the block of proton translocation and 
a reduction of the membrane potential. In 143B cells overexpressing IF1, the 
decrease of the fluorescence is greater as shown by the quantification (figure 
26, lower panel). This decrease confirms that the clone overexpressing IF1 is 
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not able to maintain the membrane potential by the hydrolysis of ATP, as 
reported by ATP hydrolysis assay , since IF1 protein binds  ATP synthase.. 
When oligomycin, a Complex V inhibitor, is added membrane potential drops 
in both cell lines, as consequence of the block of proton translocation and 
membrane depolarization . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**
**
*
*
end + AA + AA+ Oli
0
10
20
30
40
pcDNA3
pcDNA3-IF1
T
M
R
M
 f
lu
o
re
s
c
e
n
c
e
 
 
 
 
Figure 26 . Mitochondrial membran potential measured by fluorescent microscopy using the 
probeTMRM . In a) and d) is shown the endogenous membran  potential; in b) and e) cells  
have been incubated with Antimycin A (AA); in c) and f)  cells have been incubated with AA 
and oligomycin.In the lower panel TMRM fluorescence was quantified using the software 
ImageJ (*p value<0.05 respect to pcDNA3 end; **p valu<0.05 respect to pcDNA3-IF1 end). 
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Discussion 
 
The aim of this project was to study how cells reply to a modulation of IF1 
expression, when they are cultured in physiological oxygen levels (21%) or in 
low oxygen conditions, mild hypoxia (1%) or severe hypoxia (0.5%).  
Most of the work for this study has been carried out in cloning the IF1 cDNA 
into a plasmid suitable for a stable transfection and for checking that the IF1 
insertion into the plasmid did not  affect the cDNA and promoters sequences 
with  any point mutation. 
In this thesis, we showed few preliminary results obtaneid comparing the 
parental 143B cell line and the clone overexpressing IF1, cultured at 
physiological oxygen levels (21%). 
The first evidence, as shown by western blot analysis, is that in stable clone 
IF1 expression level is more than 2 times higher than in the parental cell line. 
The ATP hydrolysis assay indicated that  cells overexpressing IF1 have  
defective ATP hydrolysis ability when IF1 binding to ATP synthase is 
stimulated. This has been confirmed also by measuring the membrane 
potential in presence of antimycin A, that is lower in the clone overexpressing 
IF1, indicating  that when the Δψm drops IF1 binds to ATP synthase and 
inhibits ATP hydrolysis, that is activated to mantaine the membrane potential. 
These data indicated  that the cloning process has been seen out and that IF1 
is able to perform its physiological role in inhibiting ATP hydrolysis when the 
binding to ATP synthase is stimulated, for istance by the pH. 
Since the effect of IF1 on ATP synthesis is still unclear, this project will be 
carried on in our lab and 143B control cell line and the clone overexpressing 
IF1 will be compared in normoxia and hypoxia, to evaluate how the modulation 
of IF1 expression levels can affect the bioenergetics of these cells;  ATP 
synthesis rate will be evaluated  in addition  to ATP hydrolysis. Moreover, 
exposure of the cells to hypoxia can mimic the condition of stroke, where ATP 
consumption by the ATPase activity could represent an important pathogenic 
mechanism and it will be interesting to evaluate whether the overexpression of 
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IF1  is protective to cells and reduces cell death  in response to oxygen 
deprivation, as observed in vivo on rat heart [95]. 
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Materials and Methods 
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Cell Culture  
 
Fibroblasts were obtained from skin biopsies and cell lines were established in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 25 mM glucose 
supplemented with 15 % fetal bovine serum (FBS). During the study 
fibroblasts were cultured in DMEM containing 5 mM glucose, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B, 4 mM glutamine 
and 1 mM pyruvate.  
Fibroblasts were seeded the day before the experiments to favour adhesion, 
and after 12 hours the medium was replaced with fresh media and cells were 
cultured in two different incubators at 37°C in a humidified atmosphere of 5% 
CO
2 
under normal (21%) and low (0.5-4%) oxygen tension. Low O
2 
concentrations were obtained using the INVIVO
200 
hypoxia workstation 
(Ruskinn Technology Ltd, UK) equipped with the gas mixer Q to obtain 
accurate control and stability of O
2 
and CO
2 
concentrations. 
HDFs, HDMECs and culture media were purchased from PromoCell 
(Heidelberg, Germany). All other cell culture reagents were from Gibco 
(Stockholm, Sweden). D-Glucose and Mannitol were purchased from Sigma 
(St. Louis, MO). Cell lines were maintained in a humidiﬁed atmosphere with 
5% CO2 at 37°C in commercially supplied ﬁbroblast and endothelial cell 
growth media.  
HDF and HDMECs were established in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 5.5 mM glucose supplemented with 2 mM L-glutamine, 
100 IU/ml penicillin and streptomycin and 10 % fetal bovine serum (FBS) and 
cells between passages 4 and 9 were used. 
During the experiments cell lines were cultured in DMEM containing  5.5 mM 
glucose and 30 mM glucose in two different incubators at 37°C in a humidified 
atmosphere of 5% CO2 under normal (21%) and low (0,5-1%) oxygen tension. 
Low oxygen concentrations were obtained using the INVIVO200 hypoxia 
chamber (Ruskin Technology Ltd, UK). 
Osteosarcoma cell line 143B was cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 25 mM glucose, 1 mM pyruvate and 4 mM 
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glutamine (Sigma-Aldrich) supplemented with 10 % fetal bovine serum (FBS). 
The medium used for cell culture contained also 100 U/ml penicillin, 100 μg/ml 
streptomycin, 0.25 μg/ml amphotericin B. FBS, penicillin, streptomycin and 
amphotericin B were purchased from Gibco. 
 
 
Cell Growth Evaluation  
 
Cell growth was assayed after culturing fibroblasts in different oxygen levels 
(from 21% to 0.5%)  for 72 hours. Cells were washed with phosphate-buffered 
saline (PBS), trypsinized, collected, and the fibroblasts viability was assessed 
using trypan blue. 
 
 
Mitochondrial ATP Synthesis Assay and Cellular ATP Content 
  
The oligomycin-sensitive ATP synthase activity in permeabilized fibroblasts 
was determined according to the method described by Sgarbi et al., 2006. 
Essentially, fibroblasts (2 x 10
6 
cells/ml) were incubated for 15 min with 60 
μg/ml digitonin in a Tris/Cl buffer (pH 7.4). Complex I driven ATP synthesis 
was induced by adding 10 mM glutamate/malate (+ 0.6 mM malonate) and 0.5 
mM ADP to the sample. The reaction was stopped 3 min later by adding 
dimethylsulphoxide, and both newly synthesised ATP and intracellular ATP 
were measured by bioluminescence using a luciferin–luciferase system (ATP 
bioluminescent assay kit CLS II; Roche, Basel, Switzerland) according to the 
manufacturer's instructions. The amount of ATP measured was referred to the 
protein content, determined by the method of Lowry. The rate of ATP 
synthesis was expressed as nmol/min/mg protein and the intracellular ATP 
content as nmol/mg protein.  
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Citrate Synthase Assay  
 
The citrate synthase activity was assayed essentially as described in Trounce 
et al. 1996  [96] by incubating samples in 125 mM Tris pH 8 with 0.2% Triton 
X-100, and monitoring the reaction at 30°C by measuring 
spectrophotometrically the rate of free coenzyme A (90 μM) release at 412 nm.  
The citrate synthase activity has been considered as a general marker for 
mitochondrial volume in cells and its value was utilized for normalization of 
other mitochondrial activities. 
 
 
  
Analysis of Intracellular ROS in Live Cells  
 
Fibroblasts grown on multiwells plates for 72 hours at 21% and 1% O2, were 
washed once with PBS and loaded with 5 μM 2′,7′-dichlorofluorescin diacetate 
(DCF-DA, Molecular Probes) in complete medium without FBS for 30 minutes 
in the dark. After loading, the dye was removed by washing the cells twice with 
PBS, and intracellular ROS content was detected by measuring the 
fluorescence emission at 535 nm in a Wallac Victor2 1420 multilabel counter 
(Perkin-Elmer), according to Baracca [97]. 
 
 
 
Electrophoresis and Western Blot Analysis in Cell Lysates 
 
Fibroblasts grown for 72 hours under 21% and 1% O2  were lysed in 50 mM 
Tris, pH 8.0, 150 mM NaCl, 1% SDS, 1% Triton X-100, 0.55% DOC, 1 mM 
PMSF, and 100 μg/ml of protease inhibitors. The protein content was 
determined by Lowry method and equal amounts of cell lysate was separated 
by SDS-PAGE and blotted onto nitrocellulose membrane. 
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The membranes were saturated overnight in blocking solution (KH2PO4 1 
mM, NaCl 150 mM, NaH2PO4 3 mM pH 7,4 containing 0.05% Tween-20, 2% 
non-fat dry milk and 2% bovine serum albumin). Non-bound antibodies were 
removed by washing in PBS-0.05% Tween-20 solution.  Membranes were 
incubated with five primary mouse monoclonal antibodies specific for single 
subunits of each OXPHOS complex as follows: NDUFA9 (39 kDa) of Complex 
I, SDHA (70 kDa) of Complex II, Rieske protein (22 kDa, apparent molecular 
weight is 30 kDa) of Complex III, COX-I (57 kDa, apparent 45 kDa) of Complex 
IV, subunit β of F
1
F
0
-ATPase (52 kDa) (MitoSciences Inc., Eugene, OR, USA). 
To correct the amount of each protein complex to the cellular mitochondrial 
content, porin (31 kDa) was immunodetected with mouse anti-porin primary 
antibody (Molecular Probes).  
 
 
Intracellular ROS measurement by flow citometry 
 
HDF and HDMEC were seeded in multiwells plates in 5.5 mM glucose and 
after 18 hours the media was replaced starting the treatments in 
hyperglycemia (30 mM glucose) and hypoxia (1% oxygen tension). After 5 
days, cells were washed once with Phosphate Buffered Saline (PBS) and 
loaded with 5 µM Mitososx Red (Molecular Probes) and carboxy methyl 2’-7’ 
dichlorofluorescin diacetate (CMDCF-DA, Molecular Probes) in complete 
medium devoid of FBS for 3 hours minutes in the dark. After probe staining 
cells were harvested, washed twice with PBS and Mitosox Red and DCF 
fluorescence, index of intracellular ROS content, were detected by flow 
cytometry (Cyan, Beckman Coulter). 
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Annexin V-FITC/PI staining  
 
To assess the extent of apoptosis induction after hypoxic and hyperglycemic 
treatments, flow cytometric analysis of Annexin V-FITC/PI-stained samples 
was performed. 
HDMEC cells were seeded in multiwells plates at a density of 2500/cm2 in 
complete medium containing 5,5 mM glucose. After 18 hours media were 
replaced and treatments in hyperglycemia and hypoxia (0,5%) started. After 5 
days cells were detached, washed once in PBS and resuspended in Annexin 
V/PI (Bender MedSystem GmbH), according to manufacture instructions. 
Samples were analyzed by Cyan flow cytometer (Beckman Coulter, Miami, FL, 
USA) and at least 20.000 events per sample were acquired. 
 
 
mtDNA copy number 
 
To determine the amount of mtDNA present in each experimental condition, 
we used quantitative real-time PCR (qPCR) by measuring the ratio between 
the mitochondrial genes cyt b and 16S rRNA and the nuclear gene GAPDH. 
Total DNA was extracted from HDF and HDMEC cells cultured in different 
glucose concentrations and oxygen tensions. Total DNA was extracted by 
means of QIamp DNA Blood Mini kit (QiAgen, Sweden) according to the 
manufacturer’s instructions and the DNA concentration was measured by a 
NanoDrop ND-1000 spectrophotometer. To determine the ratio of 16S 
rRNA/GAPDH and cytb/GAPDH, qPCR was performed in an Applied 
Biosystems 7300 unit using Platinum SYBR Green quantitative PCR 
Supermix-UDG with ROX reference dye (Invitrogen). The primers used for 
cytb, 16s RNA and GAPDH amplification were synthesized by MWG Operon  
(Germany) and the sequences were as follows:  
Cyt b                    sense: 5’-ACATCGGCATTATCCTCCTG-3’ 
                             antisense: 5’-GTGTGAGGGTGGGACTGTCT-3’ 
16s rRNA   sense: 5′-ACTTTGCAAGGAGAGCCAAA-3′, 
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antisense: 5′-TGGACAACCAGCTATCACCA-3′.  
GAPDH   sense: 5′-GGATGATGTTCTGGAAGAGCC-3′,  
antisense: 5′-AACAGCCTCAAGATCATCAGC-3′.  
PCR reactions were carried out under standard conditions, with 40 cycles 
using 5 ng of total DNA template in a 20 μL volume, containing SYBRGreen 
Supermix (including MgCl2, DNA polymerase, dNTP and SYBR) and 10 pmol 
of each primer. PCR cycles were performed as follow: 15 seconds of 
denaturation step at 95°C, and 15 seconds of hybridization and extension step 
at 60°C. The results are shown as Δ(ΔCt) values, ΔCt= Ctcytb or 16s rRNA – 
CtGADPH, ΔΔCt =ΔCt sample – ΔCt CTRL. 
 
 
Plasmid Construct 
 
To generate an eukaryotic expression vector to allow for a stable cell line 
transfection we used the pCMV6-XL4 True Clone plasmid containing human 
ATPase-IF1 variant 1 cDNA (Origene) and the pcDNA3 plasmid with Neomycin 
resistance as selectable marker (Invitrogen). 
Briefly, IF1 cDNA fragment was liberated from pCMV6-XL5 digesting the 
plasmid with Not I restriction enzyme for 4 hours at 37°C, according to the 
manufacture instructions, being present two Not I sites flanking the cloning site 
of the plasmid. IF1 insert has been separated from the plasmid by 1% agarose 
gel electophoresis and afterwards has been purified with the Wizard SV Gel 
and PCR Clean-up System (Promega). Concomitantly pCDNA3 plasmid has 
been linearized with Not I restriction enzyme (as described above) and then 
purified in 1,2 % agarose gel electrophoresis. Linear pCDNA3 was treated with 
tSAP enzyme (Promega) for 45 minutes at 37°C, to avoid the recircularization 
of the plasmid. To stop the tSAP treatment, the reaction mixture was heated at 
75°C for 15 minutes. Finally tSAP treated linear pcDNA3 has been mixed with 
the IF1 fragment in a ligation reaction with T4 Ligase enzyme (Promega), for 3 
hours at room temperature to obtain the circular pcDNA3-IF1. 
 
88 
 
Bacterial Transformation 
 
Competent DH5α- E. Coli cells were transformed following standard protocol. 
Briefly, the ligation products were added to the bacteria, left in ice for 10 
minutes, heated at 42°C for 45 seconds and cooled 2 minutes in ice. Than 
bacteria were grown for 1 hour in 1 ml of SOC medium, composed of 20 gr/L 
LB broth , 1M MgCl2 , 1M MgSO4, 2M Glucose (Sigma-Aldrich). Bacterial 
colonies transformed with pCDNA3-IF1 plasmid were selected in 35 gr/L LB 
agar plates containing 100 µg/ml Ampicillin (Sigma-Aldrich). 
Each colony was collected, expanded at 37°C overnight in 20 gr/L LB broth 
with 100 µg/ml Ampicillin and finally the plasmid DNA was purified from 
bacteria using Pure Yeld plasmid Miniprep kit (Promega), according to 
manufacture instructions. 
Four purified plasmids were selected and IF1 corrected orientation was 
checked by PCR, using the following pairs of primers: T7 promoter forward 
primer 5’-TAA TAC GAC TCA CTA TAG GG-3’ and the reverse internal primer 
R4 5’-AAA TAT CGT TCC TCT TCA GC-3’. 
To check for the absence of point mutation in the IF1 cloned fragment we also 
sequenced each plasmid DNA using the T7 promoter forward primer and BGH 
reverse primer 5’-TAG AAG GCA CAG TCG AGG-3’. 
 
 
Cell transfection 
 
143 B cells were seeded the day before transfection in 35 mm plates. Seeding 
depends on cell lines growth and the transfection was performed when the 
confluence was about 40-60%. 
The following day, the medium was replaced with 2 ml of DMEM (non so se è 
complete o devoid of FBS) (Sigma-Aldrich). 2µg of both pCDNA3-IF1 and 
pcDNA3 empty plasmids have been incubated, separately, with PEI- 
Polyethylenimine linear, MW ~25,000 (Polysciences, Inc) in DMEM for 20 
minutes, using a 3:1 PEI:DNA ratio. The transfection mix was added to the 
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cells and 18-24h after transfection the medium was replaced with fresh 
medium containing 500 µg /ml of G418. to select clones over-expressing IF1 
.After two weeks of selection, cell clones overexpressing IF1 were evaluated in 
by Western Blotting and the clone with the highest expression of IF1 were 
chosen to be expanded and used in the experiment 
 
 
Mitochondrial Isolation 
 
Two 143B clones, carrying the pCDNA3-IF1 and the empty pCDNA3 plasmids 
respectively, have been harvested and resuspended in extraction buffer pH 
6.7 (0,07 M saccarose, 0,22 M manitol, 20 mM HEPES, 1 mM EDTA, 100 µM 
EGTA, 0.4% BSA). Cells have been mechanically disrupted using Potter- 
Elvehjem homogenizer and mitochondria were obtained by differential 
centrifugations and finally resuspended in two HEPES-buffer (20 mM HEPES, 
2 mM MgCl2, 1 mM ATP) differenig by the pH: pH 6.7 was used to facilitate 
IF1 binding to ATPase and pH 7.4 to conversely maintein IF1 in the unbound 
form. Protein content was assessed spectrophotometrically (λ= 750 nm) by 
Lowry’s method in presence of 0.3% (w/v) sodium deoxycholate. Bovine 
serum albumin was used as standard.  
 
 
ATP hydrolysis Assay 
 
ATPase activity was determined spectrophotometrically measuring the 
oxidation of NADH at 340 nm obtained coupling two reactions catalysed by 
pyruvate kinase (PK) and lactate dehydrogenase (LDH) respectively in 
presence of phosphoenolpyruvate (PEP).  
The assay was performed in 25 mM TRIS/acetate pH 7.4, 25 mM KOH, 5 mM 
MgCl2 and 30 µg of mitochondria were incubated with 4mM ATP, 160 µM 
NADH, 5 µM Rotenon, 1,5 mM PEP and LDH/PK. F1Fo ATPase activity has 
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been calculated as the difference between total and oligomicin-sensitive 
ATPase activity and finally was expressed as nmol/min/mg. 
 
 
Mitochondrial membrane potential  
 
Mitochondrial membrane potential in intact cells was evaluated by incubating 
cells over-expressing IF1 and cells carryng the empty vector with 20 nM 
Tetramethyl Rhodamine Methyl Ester (TMRM, Molecular Probes) for 30 
minutes at 37°C in a humidified atmosphere of 5% CO2 21% O2. Cells were 
incubated in control conditions, in presence of 1 µg/ml antimycin A and in 
presence of antimycin A plus/together with 2 µM oligomycin. Images were 
acquired using a fluorescence inverted microscope (Olympus IX50). Antimycin 
A and oligomycin where purchased from Sigma-Aldrich. TMRM fluorescence 
intensity was evaluated by means of Image J software (http://rsbweb.nih.gov). 
 
 
Statistic analysis 
Differences of each experimental condition were evaluated by one-way 
ANOVA as appropriate, using Dunnett test  and two-way ANOVA with 
Bonferroni post-hoc test. A p-value < 0.05 was considered statistically 
signiﬁcant. 
For ATP hydrolysis experiments, differences were evaluating by Student t test 
and p-values <0.05 were considered statistically significant. 
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